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ABSTRACT 
Cancer of the cervix uteri is the second most common cancer in women in the less 
developed countries and the eleventh in the more developed countries. Human 
papillomavirus (HPV) types 16 and 18 are the most prevalent and important risk 
factors for cervical cancer among the 12 oncogenic, high-risk (hr) HPV types, 
deemed to be carcinogenic in the cervix (IARC 2012a). Cervical infection with more 
than one hrHPV type is not uncommon, complicating assignment of (causal) 
carcinogenicity (Clifford et al. 2011). There are also non-oncogenic, low-risk (lr) 
HPV types, such as types 6 and 11, which cause benign lesions. Only a small 
proportion of women with cervical HPV infection(s) develop cervical cancer. 
Therefore, joint effects between different HPV types and putative co-factors in 
cervical carcinogenesis are of interest. For example, infection with Chlamydia 
trachomatis and tobacco smoking have been associated with an increased risk of 
cervical cancer also among hrHPV-positive women. Very little is, however, known 
about the interplay between these factors during cervical carcinogenesis. 
The primary objectives of this work were 1) to identify joint effects of past 
infections with the hr and lrHPV types, 2) to identify joint effects of past infections 
with hrHPV types and C. trachomatis in the etiology of cervical cancer and 3) to 
reveal the chain(s) of events between the different HPV infections and the co-factors 
by investigating the order of solitary and joint effects of persistent and incident HPV 
and C. trachomatis infections on the risk of developing cervical cancer. 
For the first two primary objectives, two case-control studies were nested within 
a joint cohort of three and four population-based Nordic biobanks to which 626 900 
and 974 000 women donated serum or blood samples by the end of 1994 and 2002, 
resprectively. In the first study with a shorter follow-up, (Study I), linkage to cancer 
registers identified 182 cases of invasive cervical carcinoma (ICC) with a donated 
serum sample before diagnosis. In Study II, the number of cases after re-examination 
of Study I histologies was 178; of these 148 were squamous cell carcinomas (SCCs). 
The material of the Study III with a longer follow-up comprised 604 ICC cases. 
Study III did not share any cases with Studies I and II. Three and five controls per 
case were randomly selected in Studies I and III, respectively. Material was 
restricted to women and matching was individual for age at serum sampling (±2 
years), storage time of the first serum sample (±2 months), region and donor 
subgroup (participant in health examinations, blood donor). 
For the third primary objective, a case-control study in a serial setting was nested 
within a cohort of women from the county of Västerbotten, who participated in a 
population-based, invitational cervical cancer screening programme in 1969–1995. 
In Study IV, 118 invasive cervical cancer cases were identified, and one control with 
two normal smears was age, and sampling-time matched to each case. In addition, a 
case-cohort study in the Finnish Maternity Cohort was based on women with a 
minimum of two pregnancies within 5 years (Study V). At the midpoint of the 
pregnancies, in 1995–2003, women were under 29 years of age, and were followed  
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on average for 4.8 years, from the second pregnancy sample until the end of 2004. 
Follow-up of 490 women ended at diagnosis of cervical high-grade precancer. For 
comparison, a subcohort of 2796 women was randomly selected by sampling from 
strata defined by age and calendar time. 
IgG antibodies to capsids of HPV types 6, 11, 16, 18, 31, 33 and 45, C. 
trachomatis and herpes simplex virus type 2 were determined by ELISA methods. 
Serum cotinine, a marker for recent smoking, was measured by radioimmunoassay 
(Studies I and II) and by semiquantitative enzyme immunoassay (Study III). HPV 
DNA in the biopsy specimen of the cases was examined by polymerase chain 
reaction (PCR) in Studies II and III. HPV DNA-positive specimens were typed with 
E6 and E7 type-specific primers (Study II) and by enzyme immunoassay and reverse 
dot blot hybridization or multiplex fluorescent bead-based assay (Study III). All 
smears and biopsies for the cytological serial sample study (Study IV) were 
examined for HPV and C. trachomatis DNA by PCR. 
Rate ratios and 95% confidence intervals were estimated by conditional logistic 
regression. In Study V, rate ratios and 95% confidence intervals were estimated 
fitting pseudolikelihood by Cox model with separate strata-specific baseline hazards. 
Misclassification of HPV serology was corrected for by back-calculus or by using as 
a gold standard the rate ratio for SCC related to HPV type 16 DNA positivity before 
diagnosis. 
In the earlier seroepidemiological nested case-control study, we found no excess 
risk of cervical carcinoma among women seropositive for both HPV16 and non-
oncogenic HPV types. In the later study, there was 2.4-fold excess risk, but the joint 
effect was again significantly smaller than the expected additive and multiplicative 
joint effects. Most importantly, we showed that if infection with major lrHPV type 6 
preceded infection with hrHPV type 31, there was little excess risk of in situ cervical 
carcinoma; and in HPV18 DNA-positive ICCs, HPV16 seropositivity was associated 
with no excess risk. The antagonistic interaction, i.e. a joint effect smaller than  
expected, between different HPV types was probably due to a cell-mediated immune 
reaction (surveillance), of which the serum antibodies were a surrogate. The risk of 
ICC was highly increased not only among women whose first smear was HPV DNA-
positive but also among C. trachomatis DNA-positive women. The risk was even 
higher among those, who were DNA positive (HPV or C. trachomatis) both at the 
start and end of follow-up. The risk of in situ cervical carcinoma was highly 
increased among women whose HPV18/45 and C. trachomatis infections were 
incident if not concomitant within a narrow time window. The risk of SCC was 
increased related to C. trachomatis, after adjusting for HPV, both in the total 
material and in the strata of HPV16 and HPV18 seronegatives and -positives. 
C. trachomatis should not be ignored in the preventive efforts against cervical 
cancer. These studies support early HPV vaccination in cervical cancer prevention. 
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TIIVISTELMÄ 
Kohdunkaulan syöpä on kehitysmaiden naisten toiseksi yleisin, ja kehittyneiden 
maiden naisten yhdenneksitoista yleisin syöpä. Kahdestatoista, syöpävaarallisesta, 
suuren riskin (hr) ihmisen papilloomaviruksen (HPV) tyypistä tyypit 16 ja 18 ovat 
tärkeimmät kohdunkaulan syövän riskitekijät. Kohdunkaulassa niitä pidetään 
karsinogeenisinä (IARC 2012a). Kohdunkaulan infektoituminen useammalla kuin 
yhdellä hrHPV-tyypillä ei ole harvinaista, ja voi tehdä tyyppikohtaisen kausaalisen 
karsinogeenisuuden määrittämisen vaikeaksi (Clifford et al. 2011). Tunnetaan myös 
pienen riskin (lr) HPV-tyyppejä, kuten HPV6 ja HPV11, jotka aiheuttavat hyvän-
laatuisia kohdunkaulan limakalvovaurioita. Vain pienelle osalle naisista, joilla on 
kohdunkaulan HPV-infektio/infektioita, tulee kohdunkaulan syöpä. Tämän vuoksi 
yhteisvaikutukset eri HPV-tyyppien ja mahdollisten kohdunkaulan syövän 
lisäriskitekijöiden välillä ovat mielenkiintoisia. Esimerkiksi Chlamydia trachomatis  
-infektio ja tupakointi on liitetty lisääntyneeseen kohdunkaulan syövän riskiin, myös 
hrHPV-positiivisilla naisilla. Näiden tekijöiden yhteisvaikutuksista tiedetään 
kuitenkin hyvin vähän. 
Tämän työn päätavoitteet olivat: 1) identifioida aiempien hrHPV- ja lrHPV-
infektioiden yhteisvaikutukset, ja 2) identifioida aempien hrHPV- ja C. trachomatis  
-infektioiden yhteisvaikutukset kohdunkaulan syövän synnyssä sekä 3) selvittää eri 
HPV-infektioille ja lisäriskitekijöille altistumisen järjestyksen merkitystä 
kohdunkaulan syövän kehittymisessä tutkimalla persistoiviin ja insidentteihin HPV- 
ja C. trachomatis -infektioihin liittyviä, näiden tekijöiden omia ja yhteisvaikutuksena 
syntyviä riskejä. 
Kahta ensimmäistä päätavoitetta varten käytettiin kahta tapaus-verrokkiaineistoa. 
Ne olivat peräisin kolmesta ja neljästä väestöpohjaisesta, pohjoismaisesta 
biopankista, joihin 626 900 ja 974 000 naista oli antanut seerumi- tai verinäytteen 
vuosien 1992 ja 2002 loppuun mennessä. Edellisessä tutkimuksessa, osajulkaisussa 
I, jossa oli lyhyempi seuranta-aika, syöpärekistereihin yhdistämisissä löydettiin 182 
invasiivista kohdunkaulan syöpätapausta (ICC), jotka olivat antaneet näytteen ennen 
diagnoosia. Osajulkaisussa II tapausten määrä oli histologisen uudelleenluokittelun 
jälkeen 178, joista 148 oli kohdunkaulan levyepiteelisyöpiä (SCC). Jälkimmäinen 
tutkimus, osajulkaisu III, sisälsi 604 ICC-tapausta, jotka eivät kuuluneet edelliseen 
tutkimukseen. Tapausta kohti valittiin satunnaisesti kolme ja jälkimmäisessä 
tutkimuksessa viisi verrokkia, jotka kaltaistettiin tapauksen sukupuolen, 
näytteenottohetken iän (+/-2 vuotta), näytteen säilytysajan (+/- 2 kuukautta), alueen 
ja osapopulaation (verenluovuttajat, terveystutkimukseen osallistuneet) suhteen. 
Kolmatta päätavoitetta varten oli käytettävissä Västerbottenin läänin kohorttiin 
upotettu tapaus-verrokkiaineisto, jossa oli käytössä perättäisiä näytteitä kohdun-
kaulan syövän seulontaan vuosina 1969–1995 osallistuneista naisista. Osajulkaisussa 
IV oli 118 invasiivista kohdunkaulan syöpätapausta, joista jokaiselle oli 
käytettävissä näytteidenottoikien ja näytteidenottoajankohtien suhteen kaltaistettu 
verrokki. Lisäksi osajulkaisun V tapaus-kohorttitutkimus perustui Äitiysneuvola-
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seerumipankkiin (FMC) näytteen antaneisiin naisiin, joilla oli ollut kaksi raskautta 
alle 29-vuotiaina, ja joita oli seurattu keskimäärin 4,8 vuotta toisen 
raskausnäytteenoton jälkeen aina vuoteen 2004 asti. Seuranta päättyi 490 naisella 
kohdunkaulan syövän pisimmälle kehittyneen esiasteen diagnoosiin. Mainitut ehdot 
täyttäneistä naisista poimittiin satunnaisesti 2 796 naisen alikohortti, joka oli ositettu 
iän ja näytteenoton kalenteriajankohdan suhteen. 
IgG-vasta-aineet HPV-tyypeille 6, 11, 16, 18, 31, 33 ja 45, sekä klamydialle että 
herpes simplex -virus tyyppi 2:lle määritettiin ELISA-menetelmillä. Äskettäiseen 
tupakointiin viittaava merkkiaine, seerumin kotiniini, määritettiin 
radioimmunoanalyysilla osajulkaisuissa I ja II ja semikvantitatiivisella entsyymi-
immunoanalyysilla osajulkaisussa III. HPV DNA osoitettiin biopsianäytteistä 
polymeraasiketjureaktiolla (PCR) osajulkaisuissa II ja III. HPV DNA -positiiviset 
löydökset tyypitettiin tyyppispesifisillä E6- ja E7-alukkeilla osajulkaisussa II, ja 
multiplex-menetelmällä osajulkaisussa III. Kaikki osajulkaisun IV sytologiset ja 
biopsianäytteet tutkittiin HPV ja C. trachomatis -DNA:n suhteen PCR-menetelmällä. 
Tiheyssuhteet ja niiden 95 %:n luottamusvälit estimoitiin ehdollisella logistisella 
regressiolla. Osajulkaisussa V tiheyssuhteet ja niiden 95 %:n luottamusvälit 
estimoitiin Coxin regressiomallilla käyttämällä ositekohtaisia riskitiheyksiä. HPV-
serologian virheluokitusta korjattiin käyttämällä kultastandardina SCC-diagnoosia 
edeltävän HPV16 DNA -positiivisuuden tiheyssuhdearviota. 
Aikaisemmassa seroepidemiologisessa, upotetussa tapaus-verrokkitutkimuksessa 
ei havaittu kohdunkaulan syövän lisäriskiä naisilla, joilla oli vasta-aineita sekä 
HPV16:lle että ei-syöpävaarallisille HPV-tyypeille. Myöhemmässä tutkimuksessa 
riski oli 2,4-kertainen, mutta yhteisvaikutus oli edelleen merkitsevästi pienempi kuin 
mitä oli odotettavissa additiivisen tai multiplikatiivisen yhteisvaikutuksen 
perusteella. Suuren riskin HPV31-infektioon liittyvä kohdunkaulan syövän 
pisimmälle kehittyneen esiasteen riski lähes katosi, jos nainen oli aikaisemmin 
sairastanut HPV6-infektion. Myöskään HPV18 DNA -positiivisilla ICC-tapauksilla 
(aikaisempi) HPV16-seropositiivisuuteen ei liittynyt lisäriskiä. Antagonistiset, 
odotettua pienemmät eri HPV-tyyppien yhteisvaikutukset luultavasti selittyvät 
soluvälitteisellä immuniteetilla, jonka surrogaattina seerumin vasta-aineet toimivat. 
Naisilla, joilla oli HPV DNA -positiivinen tai C. trachomatis DNA -positiivinen 
sytologinen löydös, oli suuresti kohonnut ICC:n riski. Riski oli vielä suurempi 
naisilla, jotka olivat joko HPV tai C. trachomatis DNA -positiivisia sekä seurannan 
alussa että lopussa. Kohdunkaulan syövän pisimmälle kehittyneen esiasteen riski oli 
merkittävästi koholla naisilla, joilla oli joko yhtäaikaiset tai lähellä toisiaan 
tapahtuneet HPV18/45- ja C. trachomatis -infektiot. C. trachomatis -infektioon 
liittyi lisääntynyt levyepiteelisyövän riski HPV-vakioinnista huolimatta niin 
HPV16/18-seronegatiivisten kuin -seropositiivisten ositteissa. 
Klamydiaa ei saisi unohtaa kohdunkaulan syövän ehkäisyssä. Tutkimustulokset 
tukevat HPV-rokotuksia nuorella iällä. 
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ABBREVIATIONS 
C. trachomatis Chlamydia trachomatis 
CD4+ level  CD4+ T cell count/mm
3
 of blood or T helper cell  
count/mm
3
 of blood 
CI  Confidence interval 
CIN  Cervical intraepithelial neoplasia 
CIN 2 Cervical intraepithelial neoplasia grade 2: moderate 
dysplasia 
CIN 3 Cervical intraepithelial neoplasia grade 3: severe 
dysplasia or carcinoma in situ 
CIS  Carcinoma in situ 
ELISA  Enzyme-linked immunosorbent assay 
GP5+/6+ General primer 5+/6(+)-mediated polymerase chain 
reaction assay 
HIV  Human immunodeficiency virus 
HPV  Human papillomavirus 
hrHPV  High-risk human papillomavirus 
HSIL  High-grade squamous intraepithelial lesion 
HSV-2  Herpes simplex virus type 2 
IARC  International Agency for Research on Cancer 
ICC  Invasive cervical carcinoma 
ICD  International Classification of Diseases 
ICD-O  International Classification of Diseases for Oncology 
IgG  Immunoglobulin G 
lrHPV  Low-risk human papillomavirus 
MONICA Multinational Monitoring of Trends and Determinants in 
Cardiovascular Disease 
NBSBCCC Nordic Biological Specimen Banks working group on 
Cancer Causes and Control 
OC  Oral contraceptive 
OR  Odds ratio 
PCR  Polymerase chain reaction 
RR  Rate ratio 
SCC  Squamous cell carcinoma 
SIR  Standardized incidence ratio 
STI  Sexually transmitted infection 
VIP  Västerbotten Intervention Programme 
VLP  Virus-like particle 
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1 INTRODUCTION 
Cancer of the uterine cervix is the second most common cancer in the less developed 
countries and the eleventh in the more developed countries (Ferlay et al. 2013). The 
aetiology of invasive cervical carcinoma is better known than that of cancers in most 
of the other anatomical sites. Sufficient evidence is reported to exist for the 
carcinogenicity of 12 human papillomavirus (HPV) types, most notably types 16 and 
18, in the cervix uteri (IARC 2012a). These high-risk (hr) HPV types are sexually 
transmitted. Persistence of at least one hrHPV type in the cervix is considered to be a 
prerequisite for the progression of transformed cells to precancer, and finally, 
invasion. 
Low-risk (lr) HPV types, 6 and 11, cause benign genital lesions. Oncogenic HPV 
infections are more likely to persist in women with a previous C. trachomatis 
infection (Samoff et al. 2005, Silins et al. 2005), which is the most common sexually 
transmitted bacterial infection and apparently is independently associated with 
cervical neoplasia (Lehtinen et al. 2011). Smoking has been associated with an 
increased risk of cervical squamous cell carcinoma, the most common morphological 
type of invasive cervical carcinoma, among hrHPV-positive women (International 
Collaboration of Epidemiological Studies of Cervical Cancer 2006a) and hrHPV 
seronegative and -positive women (Kapeu et al. 2009). 
Cervical co-infection with at least two HPV types and subsequent acquisition of a 
new HPV type is quite common among HPV-infected women (Thomas et al. 2000, 
Clifford et al. 2005, Mendéz et al. 2005). However, the joint effects of HPV types, 
interactions between high- and low-risk HPV types and co-factors, such as 
Chlamydia trachomatis and smoking, on the risk of invasive cervical carcinoma are 
not well known. 
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2 REVIEW OF THE LITERATURE 
2.1 DESCRIPTIVE EPIDEMIOLOGY OF CERVICAL 
NEOPLASIA 
2.1.1 WORLDWIDE 
 
Cervical cancer is the most common cancer of women in Eastern and Middle Africa 
(Ferlay et al. 2013, 2014). An estimated 445 000 new cases of cervical cancer 
occurred in 2012 in the less developed countries (i.e., world excluding Europe, 
Northern America, Japan, Australia and New Zealand). Cervical cancer accounts for 
12% of all cancers (non-melanoma skin cancer excluded) in women in the less 
developed countries. Only cancer of the breast is more common.  
The burden of cervical cancer is higher in less developed than more developed 
countries. Of the new cervical cancer cases worldwide, 84% were from the less 
developed countries in 2012, whereas 57% of all new female cancer cases were from 
the less developed countries. In the more developed countries, cervical cancer 
accounts for 2.9% of all the female cancers, and cervix uteri is the eleventh among 
the primary sites of cancer. 
The highest cervical cancer risk areas in terms of age-adjusted (world standard 
population) incidence rate are Eastern, Southern and Middle Africa and Melanesia. 
The age-adjusted incidence rate exceeds 30 per 100 000 woman-years in these areas, 
whereas in the low-incidence areas, Western and Eastern Asia, Australia, New 
Zealand, Northern America, Northern Africa, Northern, Southern and Western 
Europe and Micronesia, it is below 10 per 100 000 woman-years. The extremes on 
the country level are even more outstanding, 2.0 per 100 000 woman-years in the 
State of Palestine and 76 in Malawi. The cumulative risk of developing cervical 
cancer before age 75 is 1.4% worldwide, 1.6% in the less developed countries and 
0.9% in the more developed countries. On the country level, the cumulative risk 
ranges from 0.2% to 7.4%. 
Cervical cancer is the second most common cancer of women in the age group of 
15–44 years, in both the less and more developed countries. The age-specific 
incidence rate is lower among women aged 15–39 years in the less developed 
countries, 7.9 per 100 000 woman-years, than in the more developed countries, 9.7, 
but higher in the older age groups. In the less developed countries, the incidence rate 
estimate is almost constant, 44–46 per 100 000 woman-years, among 50- to 69-year-
old women, declining thereafter. In the more developed countries, the incidence rate 
is almost constant, 21–22 per 100 000 woman-years, among 40- to 59-year-old 
women, declining thereafter. Before screening in the more developed countries, the 
incidence rates increased steeply until middle age, typically attaining a peak of at 
least 50 per 100 000 woman-years and decreasing with age (Gustafsson et al. 1997). 
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The incidence rates of cervical cancer decreased during 1973–1987 in most of 
these countries for which cancer incidence data for that period are available 
(Coleman et al. 1993). Cervix uteri ceded its place as the leading cancer site of 
women in the less developed countries to the breast between the years 1985 and 
1990 (Parkin et al. 1999). The estimate for age-adjusted incidence rate decreased in 
the less developed countries from 18.2 per 100 000 woman-years in 1990 to 15.7 per 
100 000 woman-years in 2012, and in the more developed countries from 11.2 per 
100 000 woman-years in 1990 to 9.0 in 2008, but increased to 9.9 in 2012 (Parkin et 
al. 1999, Ferlay et al. 2010, 2013). The trend in age-adjusted incidence rate during 
the two most recent five-year periods was decreasing in several countries, except in 
the Netherlands, many Eastern European countries, Thailand and Uganda 
(Vaccarella et al. 2013a). In North Europe, the recent trend was less favourable than 
that over several decades. 
The number of new cervical cancer cases in the less developed countries is 
predicted to reach 479 000 in 2015 and 533 000 in 2020 (Ferlay et al. 2013). The 
burden of cervical cancer is predicted to increase also in the more developed 
countries, 85 000 in 2015 and 86 000 in 2020, although the number of new cases 
among women younger than 65 years is expected to decrease between the years 2015 
and 2020. 
Squamous cell carcinoma is the predominant histological type of cervical cancer, 
representing about 75% of the new cases (Vizcaino et al. 2000). The incidence rates 
of squamous cell carcinoma were, with few exceptions, decreasing in the more 
developed countries and, to some extent, also in a few less developed countries with 
time series data during 1973–1991. In several European countries, increasing cohort 
trends have been observed in generations born after 1930 (Bray et al. 2005a). 
Adenocarcinoma and adenosquamous cell carcinoma account for 10–15% of cervical 
cancer cases (Vizcaino et al. 1998). There was an upward trend in the incidence of 
adeno- and adenosquamous cell carcinoma among 25- to 49-year-old women during 
1973–1991 in several countries. A significant decrease in incidence was recorded 
only in three countries among 25- to 74-year-old women. In 12 out of 13 European 
countries, the trend in incidence of cervical adenocarcinoma for the period 1983–
1997 was estimated to have been on the rise (Bray et al. 2005b). The increases in 
risk of adenocarcinoma were typically seen in generations born since the 1940s. The 
upward trends may partly be explained by parallel declines in the incidence rates of 
unspecified cervical cancer/carcinoma, but also by changes in distribution and 
prevalence of aetiological factors as well as the inability of cytological cervical 
cancer screening to reduce the incidence of adenocarcinoma (Bray et al. 2005b). 
Cervical cancer is the third most common cause of cancer death among women 
in the less developed countries, comprising a tenth of cancer deaths (Ferlay et al. 
2013). In the more developed countries, cervical cancer is the ninth most common 
cause of cancer death, causing 2.8% of cancer deaths among women. Cervical cancer 
was the main contributor to the overall burden of age-adjusted years of life lost 
because of cancer among women in 54 countries, including India, Sub-Saharan 
Africa, Oceania (excluding Australia and New Zealand) and many Latin American 
countries, in 2008 (Soerjomataram et al. 2012). Cervical cancer made the largest 
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contribution mostly in the same countries to disability-adjusted life-years from 
cancer, sum of years of life lost because of premature cancer mortality and years 
lived with disability due to cancer. 
2.1.2 IN FINLAND, ICELAND, NORWAY AND SWEDEN 
 
The respective incidences of immediate precursors of invasive cervical cancer, 
cervical intraepithelial neoplasia (CIN) grade 3 and adenocarcinoma in situ (AIS), 
were highest, 135 and 5 per 100 000 woman-years, among 30- to 34-year-old 
Finnish women during 2004–2008 (Salo et al. 2013). The corresponding age-
adjusted incidence rates were 1.3 and 39.1. 
The incidence of invasive cervical cancer has decreased markedly in Finland 
from the late 1960s until the early 1990s mainly due to the successfully organized 
mass screening programme (Anttila et al. 1999, Nieminen et al. 1999, Engholm et 
al. 2013). According to the Finnish Cancer Registry files, only 129 new cervical 
cancer cases were diagnosed in 1991, corresponding to an age-adjusted incidence of 
2.8 per 100 000 woman-years. This incidence increased in two years to 4 and has 
since remained at this level. The mean annual number of new cervical cancer cases 
was 151 during 2007–2011, accounting for 1.2% of all (except skin, non-melanoma) 
female cancer cases (Engholm et al. 2010, 2013). The cumulative risk of developing 
cervical cancer before age 85 was 0.5%, based on incidence rates of 2007–2011. The 
age-specific rates among women <70 were less than 10 during 1998–2002, even if 
corrected for cervix-at-risk using the coefficients derived from 1995–1999 by Luoto 
et al. (2004). 
The age pattern of cervical cancer incidence was most beneficial for women born 
in the forties (Hakulinen 2004). In Finland, the cohort effects on the relative risk of 
ICC were estimated to be the smallest among women born in that decade (Vaccarella 
et al. 2013a). For women born since the late 1940s, the incidence has increased more 
steeply with age and year of birth (Anttila et al. 1999, Hakulinen 2004, Laukkanen et 
al. 2012). During the last decade, among women in the age range of 30–34 years, 
which is within the targeted age range (30–60 years) of the screening programme, 
the cervical cancer incidence has been at the same level as in the same age range 
prior to the onset of the screening programme in 1963. Furthermore, during 2007–
2011, the age-specific incidence rates were higher than 10 per 100 000 woman-years 
among 35- to 44-year-old women. The adverse changes in incidence have been 
suggested to be attributable to changes in sexual behaviour, screening attendance and 
quality of screening (Anttila et al. 1999, Nieminen et al. 2002). Laukkanen et al. 
(2003) showed that an increase in HPV16 incidence without increase in HPV6/11 
incidence among women in their twenties during 1983–1997 preceded the increase 
of ICC incidence in Finland. 
The proportion of squamous cell carcinomas was 76% prior to screening in 
1958–1962 and 62% in 2000–2009 (Lönnberg et al. 2012a). From 1955 to 1999, the 
incidence of cervical squamous cell carcinoma declined by 4.7% per year, on 
average (Bray et al. 2005a). In the nineties, the incidence increased by 8% per year. 
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The proportion of adenocarcinomas was only 6% prior to screening and 29% in 
2000–2009. The incidence rate of cervical adenocarcinomas decreased 2% per year 
among women aged 50–74 years during 1973–1991 (Vizcaino et al. 1998). Overall, 
the age-adjusted incidence of cervical adenocarcinoma has been fairly stable, and 
increasing steeply only in the nineties (Anttila et al. 1999). The annual increase in 
incidence of cervical adenocarcinoma was 2.6% during 1983–1997 among women 
aged less than 75 years (Bray et al. 2005b). The upward trend was seen among 
women born since 1945. 
In Iceland, a screening programme for cervical cancer was launched in 1964 and 
became nationwide in 1969 (Sigurdsson and Sigvaldason 2006). The age-adjusted 
incidence decreased steeply until the late seventies, reaching 9 per 100 000 woman-
years, climbed to a new peak in the early 1980s, returned to 9 per 100 000 woman-
years during the latter half of the eighties and has since plateaued (Engholm et al. 
2013). The mean annual number of new cases was 16 during 2007–2011, accounting 
for 2.5% of female cancer cases. The cumulative risk of developing cervical cancer 
before age 85 was 0.9% based on incidence rates of 2007–2011 (Engholm et al. 
2013). While the incidence rate of squamous cell carcinoma in 1964–1969 was 3.5 
times higher than in 1992–2002, that of adenocarcinoma was 2.4 times lower 
(Sigurdsson and Sigvaldason 2006). 
In Sweden, the age-adjusted incidence of cervical cancer was fairly stable at a 
level exceeding 15 per 100 000 woman-years until many counties started screening 
in the late 1960s, which was followed by a downward trend to reach a constant 
incidence of 7 since 1998 (Engeland et al. 1993, Dillner 2000a, Anttila et al. 2004, 
Engholm et al. 2013). In Finland, the age-adjusted incidence has been below 7 since 
the late 1970s. 
The age-specific incidence rates were less than 20 per 100 000 woman-years for 
all age groups during 2007–2011 (Engholm et al. 2013). The mean annual number of 
new cervical cancers, 446, diagnosed during 2007–2011, accounted for 2.0% of 
female cancer cases. The cumulative risk of developing cervical cancer before age 
85 was 0.8% based on incidence rates for 2007–2011. 
The age-adjusted incidence of squamous cell carcinoma was stable during 1958–
1967 and decreased by 3.7% per year during 1968–1995 (Bergström et al. 1999). 
The decline was modest, 0.8% per year, in the nineties (Bray et al. 2005a). 
Adenocarcinomas accounted for 5% of the cervical cancers in 1958 and for 19% in 
1995 (Bergström et al. 1999). The age-adjusted incidence of adenocarcinoma 
increased annually by 1.8% from 1958 to 1995. The annual increase in incidence 
was only 0.4% during 1983–1997 among women aged less than 75 years (Bray et al. 
2005b). 
In Norway, the age-adjusted incidence rate peaked in the middle of the seventies 
and decreased, excluding the early nineties, until the early 2000s (Engholm et al. 
2013). The age-adjusted incidence rate has been since 1999 at 9 or 10, and in 
Sweden below this figure since 1983. The cervical cancer screening programme was 
introduced in Norway in 1995 (Nygård et al. 2002). 
The age-specific incidence rates were higher than 15 in most age groups during 
2007–2011 (Engholm et al. 2013). The mean annual number of new cervical 
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cancers, 299, diagnosed during 2007–2011, accounted for 2.5% of female cancer 
cases. The cumulative risk of developing cervical cancer before age 85 was 1.0% 
based on incidence rates for the period 2007–2011. 
Squamous cell carcinomas accounted for 90% of cervical cancer during 1971–
1975 and for 81% during 1986–1990 (Bjørge et al. 1993). The incidence rate 
decreased 1.1% annually from 1953 to 1997 and 1.2% from 1988 to 1997 (Bray et 
al. 2005a). Adenocarcinomas accounted for 5% of the cervical cancers in 1971–1975 
and for 12% in 1986–1990 (Bjørge et al. 1993). The age-adjusted (European 
standard) incidence rate of cervical adenocarcinoma decreased from the peak of the 
early sixties until the end of the seventies and reached a second higher peak during 
the eighties (Bjørge et al. 1993). The annual increase in incidence was 1.1% during 
1983–1997 among women aged less than 75 (Bray et al. 2005b). The upward trend 
was seen among women born from 1930 onwards. 
Brustugun et al. (2014) estimated that the average number of years of life lost 
due to cervical cancer was 23.7 years in Norway in 2012. The loss estimate was 
smaller for all other cancer types. 
 
2.2 AETIOLOGY OF CERVICAL CANCER 
2.2.1 HUMAN PAPILLOMAVIRUS (HPV) INFECTION 
 
Human papillomavirus (HPV) is a small (8000 base pairs), unenveloped virus with 
double-stranded DNA. Each HPV type has less than 90% sequence similarity with 
other HPV types (Ylitalo et al. 2008). More than 50 distinct HPV types are known to 
infect the genital mucosa (Schmitt et al. 2013). Most genital HPV infections are 
transient, self-limited or cleared completely by the cell-mediated immune system 
(Lowy and Howley 2001). Persistent infections are of long duration. Wide variation 
exists in the definitions of persistence. According to the first summary of studies on 
persistent genital HPV infection among female populations of average risk, the 
median duration for HPV infections with types 16, 31 and 33 was longer than a year 
and with the rest of the HPV types less than a year (Rositch et al. 2013). 
The high-risk genital HPV types, e.g. 16 and 18, are sexually transmitted and 
highly transmissible (Dillner et al. 1996, Barnabas et al. 2006, Burchell et al. 2006). 
As a group, genital HPVs represent the most common sexually transmitted infections 
(STIs) (Schiffman and Kjær 2003). The prevalence of HPV in cytologically normal 
women has ranged from 1.5% (before first intercourse) to 44% (sexually active 
young) (Winer and Koutsky 2004). In a worldwide study, age-standardized HPV 
prevalence varied greatly, from 1.4% in Spain to 26% in Nigeria (Clifford et al. 
2005). There was heterogeneity in HPV type distribution between continents and 
within Asia between countries, but HPV16 was usually the most common hrHPV 
type. While HPV prevalence peaks at a younger age, in some populations a second 
peak is observed in older age groups, possibly explained by greater HPV persistence 
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(Castle et al. 2005). In Eastern Africa, up to one-half of women aged 25–34 years 
were HPV-positive (Bruni et al. 2010). New sexual partnership within the previous 
two years, life-time number of partners and husband’s extramarital relationships 
were associated with increased risk of being HPV-positive (Deacon et al. 2000, 
Vaccarella et al. 2006). 
In a longitudinal study, cumulative risk of acquiring any HPV infection was 44% 
at 3 years and 60% at 5 years among initially HPV-negative, sexually active young 
women (Woodman et al. 2001). Winer et al. (2003) reported comparable cumulative 
incidences. It has been estimated that the median time from first intercourse to first 
detection of HPV is three months (Collins et al. 2002). 
Low-risk HPV types, e.g. 6 and 11, can cause not only anogenital warts but also 
lesions up to CIN grade 2 (moderate dysplasia, CIN 2). About 90% of the anogenital 
warts are attributable to types 6 and 11. High-risk HPV types can cause cervical 
precancer, i.e. CIN 3 (severe dysplasia or carcinoma in situ) and invasive cervical 
carcinoma (ICC). Most HPV infections clear and lesions regress spontaneously. 
Molano et al. (2003) reported that HPV16 and its phylogenetic relatives, 
alphapapillomavirus types of clade 9, showed lower clearance rates than lrHPV 
types. The rate of regression decreases by severity of lesion (Myers et al. 2000). In a 
study on sexually active young women, 7% of those with incident HPV16 or HPV18 
infection were diagnosed with CIN 3 during a follow-up of three years (Winer et al. 
2005). The median incubation period between HPV16 infection and diagnosis of 
cervical carcinoma in situ (CIS) is estimated to be 7–12 years (Ylitalo et al. 2000a). 
Progression from untreated CIN 3 to ICC is highly probable. One-fifth and almost 
one-third of women with minimally disturbed CIN 3 lesions were diagnosed with 
cancer of the cervix or vaginal vault within 10 and 30 years, respectively, after CIN 
3 diagnosis (McCredie et al. 2008). The cumulative incidences were even higher, 
31% and 50%, if CIN 3 was known to persist. 
Unlike other virus families, papillomavirus infection requires availability of basal 
layer cells, mucosal or epidermal, able to proliferate (zur Hausen 2002). Three early 
genes of the hrHPV genome, E5, E6 and E7, have a proliferation-stimulating 
activity. E5 stimulates cell growth in the early course of infection, complexing with 
cellular growth receptors, and prevents apoptosis following DNA damage. 
Expression of E5 is usually terminated by integration of the viral genome into the 
host chromosome. Once the hrHPV genome is integrated, the viral E2 gene 
controlling for transcription of E6 and E7 is also usually disrupted or lost (Ylitalo et 
al. 2008), which may contribute to the cells not dying from productive infection 
(directed by an intact E2 gene). E6 and E7 are crucial for cervical carcinogenesis and 
are always present in HPV-associated cervical tumour samples (Boccardo et al. 
2010, Franco et al. 2004). E7 protein is able to immortalize human keratinocytes, but 
the combination of E6 and E7 is highly efficient at immortalizing human cells 
(Moody and Laimins 2010). E6 protein binds to p53 protein, which has an important 
role in cell-cycle control. The degradation of p53 leads to loss of DNA repair 
function, and the host cell is prevented from undergoing apoptosis. E6 also activates 
telomerase expression and activity and can bind many other proteins independently 
of p53 inactivation. The main transforming protein, E7, induces uncontrolled cell 
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proliferation by binding to the retinoblastoma protein, which participates in cell-
cycle regulation. E7 also promotes a calpain-driven cleavage of the retinoblastoma 
protein (Yugawa and Kiyono 2009). E7 binds to several other cell-cycle regulators. 
E6 and E7 enable the infected cell to re-enter the replicative S phase of the cell 
cycle. The biological properties of the HPV types agree well with their 
epidemiological classification into high- and low-risk types (Muñoz et al. 2003). The 
low-risk HPV types are not able to immortalize cells (Lowy and Howley 2001). E6 
and E7 of lrHPV types have no or very low transforming activity in vitro (Villa 
2006a). 
No single gold standard HPV test exists (Gravitt and Viscidi 2004). The modern 
assays for measurement of HPV DNA, such as polymerase chain reaction (PCR), are 
of high sensitivity and specificity. Contamination is a more probable reason for false 
positivity than the assay itself (Eklund et al. 2012a). The quantity of HPV DNA 
(viral load) can be determined with real-time PCR assays (Josefsson et al. 2000); the 
currently used assays measure HPV types 11, 16 and 18 at the smallest sample 
volume (Eklund et al. 2012a). A commonly used PCR assay, general primer-
mediated 5+/6+ (GP5+/6+) (de Roda Husman et al. 1995), has poor sensitivity for 
detection of HPV52 (Chan et al. 2006). Another common PCR assay, MY09/11 
(Manos et al. 1989), substantially underdetects some genotypes (Gravitt and Viscidi 
2004). Furthermore, both of these assays are limited in their capacity to genotype 
HPV types 18, 31, 51, 52 and 58 if the specimen contains HPV type 16 (Mori et al. 
2011). Incorrect detection and typing of multiple HPV types are continuing problems 
that introduce a systematic detection bias. Formalin-fixed paraffin-embedded tissues 
are suitable for amplification by PCR (Brink et al. 2007). 
Another method for HPV detection is to amplify the chemiluminescent signal 
instead of the target DNA. Hybrid capture 2 (Qiagen, Gaithersburg, MD) is the most 
widely used commercially available signal amplification assay for clinical purposes 
(Clavel et al. 1998). It was approved by the U.S. Food and Drug Administration in 
2003 and validated clinically. It detects 13 hrHPV types, but cannot determine 
multiple infections (Gravitt and Viscidi 2004). It has lower analytical sensitivity than 
PCR assays (Snijders et al. 2003). FDA approval does not include use on formalin-
fixed paraffin-embedded tissues. As the assay detects hrHPVs only, it has been used 
in screening for HPV. In Finland, the assay was used in a randomized trial within an 
organized cervical cancer screening programme (Leinonen et al. 2013). 
Serology is a useful tool for defining past infection with HPV. Zhou et al. (1991) 
introduced HPV virus-like particles (VLPs), which are essential for HPV serology 
and development of cervical cancer vaccines (Reynolds and Tansey 2009). The 
HPV16 seroprevalence has ranged from 2% to 43% in a series of cancer-free control 
women (Winer and Koutsky 2004). In an HPV serology proficiency study, 6/10 
laboratories met the criteria of at least 50% sensitivity and 100% specificity relative 
to a standardized, HPV16 VLP-based enzyme-linked immunosorbent assay (ELISA) 
(Eklund et al. 2012b). The sensitivity to detect an incident HPV16 infection by 
serological HPV16 VLP enzyme immunoassays is approximately 65% (Kjellberg et 
al. 1999, Carter et al. 2000, Gravitt and Viscidi 2004). The VLP assays of other 
HPV types probably have a sensitivity comparable with the HPV16 VLP assay, 
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except for HPV18, with a reported sensitivity within the range of 35–55%, although 
Kjellberg et al. (1999) have reported a similar sensitivity to detect HPV16 and 
HPV18 antibodies by the standard VLP assay. In unvaccinated populations, 
reactivity to multiple HPV VLP types is, however, more likely due to cumulative 
exposure to multiple HPV types than to serological cross-reactivity between types. 
Availability of high-quality VLPs has been a problem for laboratories worldwide 
(Eklund et al. 2012b). Neutralization assays using HPV pseudovirions are 
considered the gold standard for HPV serology (Eklund et al. 2012b). While HPV 
virions are type-specific in inducing antibodies in natural infection, artificially made 
VLPs most likely are not (Dubin et al. 2005). Especially, in large-scale studies 
ELISA is preferred to complex neutralization assays. Interlaboratory agreement is 
not good with sera from vaccinees (Ferguson et al. 2006). Moreover, the correlation 
between ELISA serology and GP5+/6+ PCR is not very good at an individual level, 
but is high at a population level (Vaccarella et al. 2010a). 
Infection with multiple HPV types as well as sequential infection with new HPV 
types seem to be common (Winer and Koutsky 2004). In a worldwide study, 9% of 
cytologically normal women were HPV-positive, 27% of whom had at least two 
HPV types (Clifford et al. 2005). In a meta-analysis of one million cytologically 
normal women, the crude and regionally adjusted HPV prevalences were 7.2% and 
11.7%, respectively (Bruni et al. 2010). One-fifth of HPV-positive women had 
infections with multiple HPV types. 
In a study on pregnant Finnish women, baseline HPV16-seropositive women 
were at threefold higher risk of later infections with HPV18 than baseline 
HPV11/16/31-seronegative women (Kaasila et al. 2009). Vice versa, baseline 
HPV18-seropositive women were at increased risk of later infection with HPV16. 
The youngest women, ≤20 years of age at first pregnancy, who were HPV18-
seropositive at baseline had a highly increased risk of later HPV11 infection. 
Rousseau et al. (2003) reported that the cumulative probability of acquisition of 
multiple (PCR-detected) HPV infections was higher for younger women (18–24 
years) than for women in older age groups. Concurrent acquisition of multiple HPV 
types or clustering of incident infections with multiple HPV types, of both low- and 
high-risk types, occurred more often than would be expected by chance (Thomas et 
al. 2000, Mendéz et al. 2005). The odds ratios (ORs) of incident, concurrent 
infections ranged from 3.3 to 25 (Mendéz et al. 2005). Vaccarella et al. (2010b) 
suggested that the excess of multiple infections was an artifact of enzyme 
immunoassay genotyping. The excess of multiple infections was not evident when 
reverse line blot was used as a genotyping method. Carozzi et al. (2012) reported 
that the observed-to-expected ratio for infections with multiple HPV types was 1.21 
(95% credible interval, 1.13–1.30), but no evidence emerged for specific HPV types 
occurring in co-infections more or less often than expected at a significance level 
0.01. In a study of Swedish subjects, the HPV type combination 18 and 6 was found 
more often than expected (Vaccarella et al. 2013b). 
In a study by Thomas et al. (2000), the risk of acquiring HPV6 infection was 
increased when it was subsequent to infection with HPV45, and vice versa. The risk 
of HPV18 infection was increased when it was subsequent to HPV6 or HPV11 
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according to study by Mendéz et al. (2005). Non-significant relations comprised 
HPV18 prior to HPV33 and HPV45, and HPV31 prior to HPV6. Thomas et al. 
(2000) reported that the risk of acquiring a new HPV type was not decreased among 
women with a prior HPV infection. Liaw et al. (2001) reported that the risk for 
acquisition of HPV types 6/11, 18 and 45 was increased among those who were 
HPV16 DNA-positive at enrolment. Rousseau et al. (2003) reported that HPV16 and 
HPV18 co-occurred with other oncogenic HPV types and with HPV6/11 less 
frequently than expected. Chaturvedi et al. (2005) found that HPV16 and its 
phylogenetic relatives, alphapapillomavirus types of clade 9, were less likely 
involved in multiple HPV infections than alphapapillomavirus types of other clades. 
Mejlhede et al. (2010) reported that all odds ratios for co-infection with HPV16 and 
each of 24 HPV types were ≤1. HPV16 did not affect the persistence of concomitant 
infections (Liaw et al. 2001). Persistence of HPV was independent of co-infection 
with other HPV types (Rousseau et al. 2001). By contrast, Ho et al. (1998) and 
Samoff et al. (2005) reported that infection with multiple HPV types was associated 
with increased risk of HPV persistence. Clearance of HPV infection has been 
suggested to be independent of co-infection with other HPV types (Liaw et al. 2001, 
Molano et al. 2003). 
Merikukka et al. (2011) reported a possible competitive advantage for HPV33 
over the genital HPV types in an unvaccinated population. A virtual longitudinal 
survey showed that cross-immunity among HPV types is consistent with current 
epidemiological data, and removal of targeted HPV types would increase the 
prevalence of non-targeted types considerably (Durham et al. 2012). On the other 
hand, type replacement is considered unlikely, and the replacing types probably 
entail a lower risk of cancer (Tota et al. 2013). According to the mathematical model 
of three or more epidemiologically interacting bacterial serotypes by Lipsitch (1997), 
it is possible that the prevalence of a non-targeted, competing serotype may increase 
more than the prevalence of a single targeted serotype decreases. It has been 
observed that replacement of pneumococcal serotypes is a combination of expansion 
of pre-existing serotypes and an introduction or identification of new serotypes 
important in invasive pneumococcal disease and/or carriage in a population (Scott et 
al. 2012). 
2.2.2  HPV AND CERVICAL NEOPLASIA 
 
Human papillomavirus (HPV) type 16 and 18 DNAs were cloned from cervical 
carcinoma biopsies in 1983 and 1984, respectively (Dürst et al. 1983, Boshart et al. 
1984). Walboomers et al. (1999) suggested that HPV is a necessary cause of 
invasive cervical carcinoma worldwide, as only two adequate cervical carcinoma 
specimens (0.3%) in their material from 22 countries were HPV-negative. There are 
genital HPV types, most notably types 16 and 18, considered to be associated with 
significantly increased occurrence of cervical carcinoma (Muñoz et al. 2003). An 
IARC working group suggested that twelve HPV types can lead to cervical cancer 
(IARC 2012a). 
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 The association between HPV and ICC has been evaluated under all proposed 
standard sets of causality criteria (Bosch et al. 2002). The association is very strong 
and universally consistent. The requirement for a biological gradient has been met 
for cervical precancer, including CIS, but not for ICC (Josefsson et al. 2000, Ylitalo 
et al. 2000b, Moberg et al. 2004, Spence et al. 2005). Experimental evidence from 
HPV vaccination studies shows that CIN 2 associated with HPV16/18 can be 
prevented by vaccination (Harper et al. 2004, Villa 2006b). However, not until ICC 
can be prevented by HPV vaccination can the role of HPV be considered causal for 
the development of ICC. To prevent ICC, it would be sufficient to remove infection 
with the hrHPVs if a hrHPV was a necessary cause of ICC. ICC is the first human 
cancer with a proposed necessary cause (Franco et al. 2004). 
The major steps in the natural history of cervical cancer are acquisition of 
hrHPV, infection persistence with at least one hrHPV type, progression to precancer 
and invasion (Schiffman and Kjær 2003). Most cervical cancers and their precursors 
develop at the transformation zone of the uterine cervix. Thus, hrHPVs must infect 
the transformation zone, where columnar cells with the potential to differentiate 
along squamous or glandular lines are located (Stoler 2004). The transformation 
zone is located at the exocervix in 94% of women younger than 25 years and moves 
to the endocervical canal with age (Autier et al. 1996). 
 According to a worldwide meta-analysis of 11 600 CIN 3 and 40 600 ICC cases, 
93% of women with CIN 3 and 89% of those with ICC were HPV DNA-positive 
(Guan et al. 2012). Among CIN 3 patients, HPV16 was the most prevalent, 59%, and 
the order of types 31, 52, 33 and 58 depended on the source of DNA. The most 
common types among ICC patients were 16 (65%), 18 (17%), 58, 33 and 45. The 
relative contribution of HPV types 16 and 18 in ICC and squamous cell carcinoma 
(SCC) of cervix uteri remained stable in a material of 11 countries from Central-
South America, Europe and Asia over seven decades until 2007 (Alemany et al. 
2014). 
 In SCC, the most prevalent hrHPV types worldwide were 16, 18, 45, 31 and 33 
(Clifford et al. 2003). In the International Agency for Research on Cancer (IARC) 
multicentre study, these five HPV types accounted for 83% of the HPV DNA-
positive SCCs and 75% of all SCCs (Muñoz et al. 2003). There were small 
differences between the regions with regard to the other hrHPVs. In a more recent 
study, the same five HPV types predominated (de Sanjosé et al. 2010). The 
proportion of HPV DNA-positives was 87%.  
 Alemany et al. (2014) reported that in 11 countries, the relative contribution of 
HPV16 in adenocarcinoma increased and that of HPV18 decreased over seven 
decades, with HPV16 becoming more prevalent than HPV18 after the 1960s. 
Clifford et al. (2003) reported in their meta-analysis that in adeno- and 
adenosquamous carcinoma of the uterine cervix, the predominant HPV type, 18, was 
followed by 16 and 45 in every region in the world. In an IARC multicentre study, 
the order of HPV types 16 and 18 was reversed, and the five most prevalent HPV 
types, 16, 18, 45, 59 and 35, accounted for 96% of the HPV DNA-positive 
adenocarcinomas and 89% of all adenocarcinomas (Castellsagué et al. 2006). In the 
more recent study, 16, 18 and 45 were the most common HPV types among both 
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adeno- and adenosquamous carcinomas, and the proportions of HPV DNA positivity 
were 62% and 81%, respectively (de Sanjosé et al. 2010). The most common HPV 
types in a precursor to adenocarcinoma, AIS, in Europe and North America were 18, 
16 and 45 (Guan et al. 2013). 
 If HPV is a necessary cause of ICC, then all cases of ICC are attributable to 
HPV infection. The estimated number of ICC cases worldwide in 2008 was 530 000, 
corresponding to 93% of cancer cases attributable to HPV, 48% of cancer cases 
attributable to any infectious agent and 8.8% of all cancer cases in women (de Martel 
et al. 2012). The pooled OR for ICC associated with the presence of HPV was 158 
(95% confidence interval (CI), 113–221), and the hrHPV type-specific pooled ORs 
were not smaller than 45 in the IARC multicentre study (Muñoz et al. 2003). The 
ORs for the strongest associations, HPV16 and squamous cell carcinoma and HPV18 
and adenocarcinoma, led to attributable risks greater than 95% (Bosch et al. 2002). 
However, as the IARC multicentre study is based on pooled cross-sectional studies, 
it does not contribute to the temporality criterion of causality. According to a meta-
analysis of longitudinal studies, the estimate for HPV-associated relative risk of 
cervical carcinoma, both invasive cervical carcinoma and carcinoma in situ, was 17 
(95% CI, 8.2–33) and the estimate for the proportion of cervical carcinoma cases 
attributable to HPV16 was 27–44% (Lehtinen et al. 2001). In the fertile-aged Finnish 
female population, 61% (95% CI, 18–85%) of SCC cases and 6% (95% CI, -19–
35%) of CIN 3 cases were estimated to be attributable to HPV16 after adjustment for 
several variables, among them invitations to organized cervical cancer screening 
(Laukkanen et al. 2010). 
2.2.3 CO-FACTORS 
 
Human papillomavirus may be a necessary but not a sufficient cause of cervical 
cancer. Only a small proportion of women with HPV infection develops cervical 
cancer. Therefore the role of co-factors in cervical carcinogenesis, e.g. how they 
modify the cancer risk among HPV-infected women, is an important issue. A 
classification of candidate co-factors into three groups has been suggested: 1) 
environmental co-factors, such as use of oral contraceptives, tobacco smoking, parity 
and other STIs; 2) host co-factors, such as endogeneous hormones and factors related 
to the host's immune response; and 3) HPV co-factors, including virus variants, viral 
load, and viral integration (Castellsagué and Muñoz 2003). The last class concerns 
HPV per se and might be called HPV factors instead of co-factors. When assessing 
the contribution of co-factors in cervical carcinogenesis, it has become a standard 
procedure to restrict the analyses to hrHPV-positive subjects. This is not necessarily 
a safe procedure because, for example, smoking and other STIs are surrogates for 
risk-taking behaviour that increases the exposure to hrHPVs (Castle and Giuliano 
2003). 
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Chlamydia trachomatis 
 
Chlamydia trachomatis is an obligate intracellular bacterium that replicates in 
cervical epithelial cells (Paavonen et al. 2003). C. trachomatis is among the most 
common STI agents, with an estimated 46 million new infections in women 
worldwide in 1995 (Gerbase et al. 1998). About three-quarters of women infected 
with C. trachomatis are symptom-free, and some C. trachomatis infections persist 
(Golden et al. 2000). C. trachomatis is a common cause of urethritis and cervicitis 
and may induce pelvic inflammatory disease (Paavonen et al. 2003). Co-infection of 
HPV and C. trachomatis may result in a more profound inflammatory state than 
HPV or C. trachomatis infections alone (Ylä-Outinen et al. 1990, Castle and 
Giuliano 2003). Oncogenic HPV infections may be more likely to persist among 
women with a previous C. trachomatis infection (Samoff et al. 2005, Silins et al. 
2005). 
Antibodies to C. trachomatis were shown to be associated with an increased risk 
of cervical precancer and cancer some time ago, but the role of HPV was not 
controlled (Schachter et al. 1982, Hakama et al. 1993). C. trachomatis seropositivity 
was associated with an increased risk of cervical squamous cell carcinoma adjusted 
for HPV or among HPV DNA-positives (Koskela et al. 2000, Smith et al. 2004, 
Castellsagué et al. 2006). There was no excess risk of adenocarcinoma among 
women seropositive for C. trachomatis in these studies. Nauclér et al. (2007) 
reported that C. trachomatis was associated with an increased risk of incident CIS+. 
Safaeian et al. (2010) reported without showing results that they failed to find any 
association between C. trachomatis IgG or DNA status and risk of CIN 3+ or ICC 
among HPV-infected women. The risk of CIN 3/AIS associated with C. trachomatis 
positivity was only slightly increased among hrHPV-positive women participating in 
the placebo arms of two multinational HPV vaccination trials (Lehtinen et al. 2011). 
Castellsagué et al. (2014) reported that mucosal-HPV L1-serology-adjusted C. 
trachomatis was associated with a non-significantly increased risk of CIN 3/CIS, but 
the risk of ICC was higher and statistically significant, with respective ORs of 1.3 
and 2.3. In two longitudinal studies, the ORs for squamous cell carcinoma were 3.0 
and 6.6 related to C. trachomatis serotypes G, F, K or G (Lehtinen et al. 1996, 
Anttila et al. 2001). In a cross-sectional IARC multicentre study, the OR for C. 
trachomatis seropositivity among HPV DNA-positives was 1.8 (95% CI, 1.2–2.7) 
(Smith et al. 2004). The risk of squamous cell carcinoma increased by C. 
trachomatis antibody titres. The proportion of cervical neoplasia attributable to C. 
trachomatis varied between 15% and 20% depending on the background prevalence 
in a meta-analysis by Lehtinen et al. (2010). 
 
 
Herpes simplex virus type 2 
 
Since the late 1960s until the 1980s, herpes simplex virus type 2 (HSV-2) was 
considered the major cause of ICC (Rawls et al. 1968, Lehtinen et al. 2002). This 
hypothesis was abandoned due to no difference in HSV-2 antibody prevalence 
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between cases and controls in a longitudinal study (Vonka et al. 1984), and 
consistent identification of HPV DNA in cervical carcinoma (Dürst et al. 1983). As 
HSV-2 DNA could not be identified consistently in cervical carcinoma, Galloway 
and McDougall (1983) proposed a “hit and run” mechanism, suggesting that HSV-2 
is an initiator in cervical carcinogenesis. In a meta-analysis of longitudinal studies, 
not a single study reported a significantly increased relative risk for cervical 
carcinoma related to HSV-2 and the weighted mean of relative risks was 0.9 (95% 
CI, 0.6–1.3) (Lehtinen et al. 2002). Recent longitudinal studies have confirmed this 
finding (Castellsagué et al. 2014). 
In the cross-sectional IARC multicentre cervical cancer study, among HPV 
DNA-positive women, HSV-2 was associated with an increased risk of squamous 
cell carcinoma and adenocarcinoma, with respective ORs of 2.2 and 3.4 (Smith et al. 
2002). A longitudinal Nordic study of invasive cervical carcinoma reported an 
increased risk of the same level during the year prior to diagnosis (Lehtinen et al. 
2002). Probably HSV-2 preferably infects cancerous tissue, and due to the fact that 
HSV-2 seropositivity is a strong marker of sexual activity (Cowan et al. 1994), 
increased risk estimates are seen in cross-sectional studies.  
 
 
Human immunodeficiency virus 
 
On the basis of a meta-analytic pooling of cross-sectional studies, HPV and human 
immunodeficiency virus (HIV) seem to interact synergistically to increase the risk of 
CIN (Mandelblatt et al. 1999). Infection with HIV causes suppression of cell-
mediated immunity, and lower CD4+ level is the marker for immunosuppression 
among HIV-positive individuals (Palefsky and Holly 2003). Among HIV-positive 
women, lower CD4+ level is related to high HPV DNA levels and a large number of 
HPV types in cervical specimens (Palefsky and Holly 2003). HIV-positive 
individuals tend to have a higher prevalence and a longer duration of genital HPV 
DNA than HIV-negative individuals (Ho et al. 1994, Winer and Koutsky 2004). 
Immunosuppression is strongly associated with the early stages of dysplasia 
(Palefsky and Holly 2003). 
 
 
Smoking 
 
Regardless of body fluid, blood, urine or saliva, cotinine, the major primary 
metabolite of nicotine, is highly specific, 99–100%, and sensitive, 96–97%, and 
currently is the most widely used biomarker of tobacco smoke uptake (Jarvis et al. 
1987). Cotinine reflects exposure to tobacco smoke over the past 2–3 days. 
Individual differences are present in the amount of nicotine converted to cotinine. 
However, the cotinine levels are clearly higher in smokers than in non-smokers and 
directly correlated with the number of cigarettes smoked per day. Both nicotine and 
cotinine have also been found in cervical mucus (Sasson et al. 1985). The mucus 
concentrations correlate with reported cigarette consumption (Schiffman et al. 1987). 
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Cotinine is the best biomarker for exposure to secondhand smoke uptake (IARC 
2004). 
In a pooled analysis restricted to the HPV-positive women of the cross-sectional 
IARC multicentre case-control study, the OR estimate for SCC associated with 
current smoking was 2.3 (95% CI, 1.3–4.0) and with smoking in past 1.8 (95% CI, 
0.95–3.4) (Plummer et al. 2003). In a collaborative re-analysis of studies, including 
also the above-mentioned ones, the respective OR estimates were 2.0 (95% CI, 1.5–
2.5) and 1.6 (95% CI, 1.0–2.6) (International Collaboration of Epidemiological 
Studies of Cervical Cancer 2006a). The respective OR estimates for adenocarcinoma 
(including adenosquamous carcinoma) were 1.1 (95% CI, 0.4–2.7) and 1.7 (95% CI, 
0.3–8.5). Heavy smoking, with high levels of serum cotinine, was associated with an 
increased risk of SCC among both HPV16/18-seronegative and -seropositive women 
(OR, 2.7; 95% CI, 1.7–4.3) (Kapeu et al. 2009). Among HPV L1-seropositive 
women, current smokers had twofold increased risks of CIN 3/CIS and ICC 
associated with smoking ≥10 years and ≥30 years, respectively, as compared with 
never-smokers (Roura et al. 2014). The HPV L1-seropositive former smokers had 
non-significantly decreased risks of CIN 3/CIS and ICC in all time categories since 
quitting smoking, relative to HPV L1-seropositive current smokers. Furthermore, the 
effect of smoking on the risk of cervical SCC did not diminish with the adjustment 
for hrHPV infection (HPV DNA detection), or in the analysis restricted to hrHPV 
DNA-positives (IARC 2004).  
Unlike SCC, cervical adenocarcinoma appears to show no clear association with 
smoking (IARC 2012b). This is a major difference between cervical SCC and 
adenocarcinoma (Berrington de González et al. 2004, International Collaboration of 
Epidemiological Studies of Cervical Cancer 2007a). An estimated 12% of HPV-
positive cervical cancer cases were attributable to ever-smoking in the IARC 
multicentre study material (Castellsagué and Muñoz 2003). Passive smoking has 
been investigated in couples where the woman has been monogamous (Louie et al. 
2011). Among them, compared with non-smoking couples, the OR was 1.6 if the 
woman was an ever-smoker and the man a non-smoker, whereas the OR was 2.3 if 
they  were both ever-smokers. 
Several biological mechanisms have been suggested for the association of 
smoking with cervical neoplasia (Szarewski and Cuzick 1998). Smoking may 
weaken the immune response to hrHPV, allowing the virus to persist longer among 
smokers than non-smokers (Barton et al. 1988). Minor-grade cervical lesions regress 
more slowly among current than past smokers (Szarewski et al. 1996). On the other 
hand, smoking was found to be protective against hrHPV persistence in two 
prospective studies (Hildesheim et al. 1994, Ho et al. 1998). According to a 
mechanism of direct effects, cigarette smoke metabolites found in the cervical tissue 
may transform cells infected by hrHPVs (Szarewski and Cuzick 1998). A 
prospective study demonstrated results supporting a promoter role of smoking in the 
early phase of cervical cancer development (Giuliano et al. 2002). Cigarette smoke 
by-products may affect the early evolution of HPV-related lesions in the 
transformation zone of the cervix uteri, possibly by increasing the rate of cell 
turnover (Cotran et al. 1989, Harris et al. 2004). 
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Parity 
 
Multiparity has for decades been suspected of being associated with an increased 
risk of cervical cancer (Muñoz et al. 2002). Parous compared with nulliparous 
women more likely have the transformation zone located on the exocervix (Autier et 
al. 1996). Autier et al. (1996) suggested that with an increasing number of livebirths 
the transformation zone is for longer periods directly exposed to external agents 
capable of inducing premalignant lesions. Seroreactivity against HPV16 is higher in 
non-pregnant women than in pregnant women, suggesting a low humoral immune 
response against HPV infections during pregnancy (Sethi et al. 1998). 
In a pooled co-factor analysis restricted to the HPV DNA-positive women of the 
cross-sectional IARC multicentre study, the OR estimate for invasive and in situ 
SCC associated with seven or more full-term pregnancies compared with nulliparity 
was 3.8 (95% CI, 2.7–5.5) (Muñoz et al. 2002). In a collaborative re-analysis of 
studies including the above-mentioned ones, the corresponding OR estimate was 5.0 
(95% CI, 3.5–7.1) (International Collaboration of Epidemiological Studies of 
Cervical Cancer 2006b). The risk of SCC increased with an increasing number of 
full-term pregnancies in most major studies on HPV-positive (restrictively) women 
(Castellsagué and Muñoz 2003). The effect of this restriction was considerable in the 
IARC study, as the OR among all women was 1.6 (95% CI, 1.2–2.2) (Muñoz et al. 
2002). The association of parity with adenocarcinoma risk was weaker than that with 
SCC risk, with the OR estimates no higher than 2.4 among HPV-positive women 
and 1.5 among all women (Berrington de González et al. 2004, Castellsagué et al. 
2006, International Collaboration of Epidemiological Studies of Cervical Cancer 
2006b). In a Finnish study of multiparous women the SCC incidence exceeded the 
national average slightly (standardized incidence ratio (SIR), 1.2; 95% CI, 1.05–1.4), 
while that of adenocarcinoma did not essentially differ from the average (Hinkula et 
al. 2004). The age at first full-term pregnancy was associated inversely with the risk 
of ICC, and this association remained within strata defined by age at sexual debut in 
the collaborative re-analysis of studies of cervical cancer (International 
Collaboration of Epidemiological Studies of Cervical Cancer 2006b). 
 
 
Oral contraceptives 
 
In vitro and in vivo experiments have revealed an effect of 16α-hydroxysterone, an 
oestrogen metabolite, in enhancing hrHPV gene activity (de Villiers 2003). This is in 
line with epidemiological studies showing an increased risk of cervical cancer 
related to long-term oral contraceptive (OC) use in HPV-infected women. In the 
pooled, cross-sectional IARC multicentre case-control study restricted to the HPV-
positive women, the OR estimate for invasive SCC associated with at least five-year 
OC use was 4.0 (95% CI, 2.0–8.0) (Moreno et al. 2002). The OR estimates did not 
vary by time since first or last use. A systematic review of 28 studies reported that 
the OR estimates in HPV-positive women associated with long-term OC use were 
broadly similar for CIS and ICC and for SCC and adenocarcinoma (Smith et al. 
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2003). A collaborative re-analysis study of individual data reported that the 
combined use of oral contraceptives for at least five years was associated with 
increased RR, 1.5, of ICC, and past use with increased RR, 1.4, of both ICC and CIN 
3/CIS, among HPV-positive women (International Collaboration of Epidemiological 
Studies of Cervical Cancer et al. 2007b). In a Finnish register-based study, 
postmenopausal oestradiol-progestagen therapy was not associated with risk of CIN 
3 or AIS lesions, but at least six-month use and at least five-year use were associated 
with decreased risk of SCC and increased risk of AC without adjustment for HPV 
status, respectively (Jaakkola et al. 2012). An estimated 4% of the HPV-positive 
cervical cancer cases were attributable to being ever-users of OCs, but 16% were 
attributable to at least a five-year use versus shorter or no use (Castellsagué and 
Muñoz 2003). 
 
 
Diet and nutrition 
 
The available evidence for an association between diet and nutritional status and 
cervical carcinogenesis taking HPV infection into account is not yet convincing 
according to a review by García-Closas et al. (2005). They suggested that folate, 
homocysteine, retinol and vitamin E are probably associated with cervical neoplasia 
and cancer. Whereas homocysteine may increase the risk of cervical neoplasia, the 
other three micronutrients may be protective. 
A prospective population-based serological study did not show any protective 
effect of serum retinol, but suggested larger than multiplicative joint effect of low 
levels of retinol and HPV (types 16, 18 and 33) seropositivity on the occurrence of 
ICC (Lehtinen et al. 1999). However, as a whole, decreased risk of ICC was 
associated with low levels of serum retinol and the lowest levels of α-tocopherol. In 
another study, low levels of serum retinol were associated with an increased risk of 
ICC, and the combination of high levels of serum retinol and HPV16 with a 
decreased risk of ICC (Lehtinen et al. 1994). Shannon et al. (2002) reported an 
increased risk of ICC to be associated with high dietary E levels (Shannon et al. 
2002). Older studies on this association have been less consistent than those on 
vitamins A and C and risk of ICC (Potischman and Brinton 1996). A serological 
case-control study suggested that β-carotene might have a protective role in the 
aetiology of cervical cancer (Potischman et al. 1991). In dietary studies, the OR 
estimates of ICC association with high versus low carotenoid levels have ranged 
from 0.5 to 1.0 (Potischman and Brinton 1996, Shannon et al. 2002). The same 
applies to studies on dietary vitamin C. In a recent, prospective questionnaire-based 
study, the only finding that remained significant after correction for measurement 
error was an inverse association between ICC and daily intake of fruit (González et 
al. 2011). Of the nutrients, vitamin C and retinol had closest to significant inverse 
associations with the risk of ICC. The risk of CIS was not associated with any 
dietary factors. 
 
  
 33 
Socio-economic status 
 
The incidence of ICC in the highest social class (based on occupational 
classification) was below the national average among Finnish women aged 45–64 
years in 1971–1995 (SIR, 0.6; 95% CI, 0.5–0.7) (Pukkala and Weiderpass 1999). 
The SIR for ICC in the lowest social class was 1.3 (95% CI, 1.2–1.4). The authors 
concluded that the observed socio-economic differences were possibly due to 
differences in lifestyles or life conditions such as viral infections, smoking, 
reproductive patterns and diet. Waiters, drivers, beverage and tobacco workers were 
among the occupations with the highest SIRs for ICC, 1.5–2.0, in Nordic countries 
in 1961–2005 (Pukkala et al. 2009). Exposure to hrHPV types and tobacco smoking 
as well as participation in cervical cancer screening programmes may vary by 
occupation. A meta-analysis of ten studies on income status and the risk of ICC 
reported an OR estimate of 2.7 (95% CI, 2.3–3.1) associated with low compared 
with high income (Parikh et al. 2003). A meta-analysis of 27 studies on education 
level and risk of ICC reported an OR estimate of 2.0 (95% CI, 1.8–2.2) associated 
with low compared with high social class (Parikh et al. 2003). The authors 
concluded that the socio-economic differences in Western Europe were primarily 
due to differences in lifestyles such as history of sexual (risk-taking) behaviour and 
elsewhere equally importantly due to differences in access to cervical cancer 
prevention programmes. It is important to note that both the acquisition of HPV 
infection and many of the co-factors are determined by risk-taking behaviour. A 
combination of two IARC multicentre studies found that the excess of ICC in 
women with five years of education or less was not explained by HPV prevalence, 
but largely by the ages at first sexual intercourse and first pregnancy (Franceschi et 
al. 2009). 
  
 
Male circumcision 
 
According to an IARC multicentre cervical cancer study, male circumcision was 
associated with a moderate, non-significant decrease in the risk of ICC in the men’s 
female partners (OR, 0.7) (Castellsagué et al. 2002). The decrease was significant if 
the women were monogamous and their circumcised male partner had a history of at 
least six sexual partners (OR, 0.4; 95% CI, 0.2–0.8). The ICC risk among 
monogamous women was non-significantly increased, if the circumcised male 
partner had less than six life-time sexual partners, (OR, 1.4). Male circumcision may 
protect against ICC by preventing HPV transmission. Circumcised men were less 
likely than uncircumcised men to have penile HPV infection (OR, 0.4; 95% CI, 0.2–
0.9) (Castellsagué et al. 2002). Women with circumcised partners compared with 
those with uncircumcised partners also had a decreased risk of testing seropositive 
for C. trachomatis (OR, 0.2; 95% CI, 0.1–0.6) (Castellsagué et al. 2005). 
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Endogeneous hormones 
 
The first prospective study on levels of circulating steroidal sex hormones and ICC 
risk found a significant positive association with free testosterone in premenopausal 
women, and with testosterone in postmenopausal women (Rinaldi et al. 2011). Sex 
hormone-binding globulin was inversely associated with ICC risk in premenopausal 
women. Oestradiol showed a non-significant positive association among 
postmenopausal women. No associations were detected between any hormone and 
risk of CIN 3. 
 
 
Genetics and immune response genes 
 
Transplant recipients tend to have higher HPV DNA prevalence or HPV antibody 
levels prior to diagnosis of skin cancer than controls (Bouwes Bavinck et al. 1993). 
High HPV DNA levels in immunosuppressed individuals support the vital role of 
cell-mediated immunity in the body's ability to clear HPV infection (Ho et al. 1994, 
Winer and Koutsky 2004). A study utilizing the Swedish Family Cancer Database 
reported that, compared with daughters of mothers without ICC, the familial relative 
risk estimate for ICC in daughters of mothers with ICC was 2.1 (95% CI, 1.7–2.4) 
(Hemminki et al. 1999). The familial relative risk estimate for ICC in mothers of 
daughters with ICC as compared with mothers of daughters without ICC was higher, 
3.9 (95% CI, 3.0–4.9). On the contrary, tobacco-, immunosuppression- and HPV-
related cancers were aggregated in the cervical cancer families. Heritability of 
liability to ICC was estimated to be between 0.22 and 0.34. According to a meta-
analysis by Castro et al. (2007), human leukocyte antigens (HLA) A11, B7 and DR2 
were identified as susceptibility genes and DR6 and B15 as resistance genes. In 
Caucasian populations, also DR10 had a significant association with susceptibility to 
cervical cancer. Castro et al. (2009) found out that variations in genes/alleles IL-6, 
LTA and DRB1*1301 were associated with a decreased risk, and genes/alleles 
CCND1, DRB1*0401 and DRB1*1501 with an increased risk of CIN 3/cervical 
cancer. The first genome-wide association study of CIS/cervical cancer confirmed 
the previously observed increased risk of CIS/cervical cancer associated with alleles 
DRB1*1501, DQB1*0602 and B*0702, and the decreased risk associated with 
alleles DRB1*1301, DQA1*0103 and DQB1*0603 (Chen et al. 2013). They found 
also three novel loci in the major histocompatibility complex region associated with 
CIS/cervical cancer. The above-mentioned genes and alleles are involved in the cell 
cycle and immune control. 
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2.3 DESIGN AND ANALYSIS OF CASE-CONTROL 
STUDIES  
 
The rationale for case-control studies is the comparison of exposure histories 
between a group of diseased cases and a group of randomly selected, non-diseased 
controls in order to find differences of importance. The first modern case-control 
studies were conducted in the 1920s, but the methodology gained popularity only 
after publication of four case-control studies successful in linking tobacco smoking 
and lung cancer in 1950 (Paneth et al. 2002, Breslow 2014). The study by Doll and 
Hill (1950, 1952) is still a model for case-control studies. Doll and Peto (pp. 1259–
60, 1981) foresaw the pertinent role of case-control design in large biobank studies 
on lifestyle and environmental aspects and risk of cancer death.  
In seroepidemiological studies, the volume of the serum sample decreases each 
time a droplet is needed for a new study. At most serum banks, the whole sample 
must be frozen and thawed, which can affect many biomarkers. Furthermore, the 
effort required to analyse the samples of all cohort members may be beyond the 
capacity of the laboratory. Valuable samples should not be wasted in full cohort 
analysis. The number of studies a serum bank can serve should be maximized by 
implementing more efficient study designs. 
Nested case-control design and case-cohort design are efficient sampling 
methods to measure exposure-disease associations in a cohort and are appropriate 
especially when a full cohort design is not feasible. The case group comprises 
preferably all cases in the study population who contracted the disease of interest 
during follow-up. The control group is a random sample of all subjects at risk in the 
study population selected at design-dependent time-points and meeting possible 
matching criteria.  
2.3.1 NESTED CASE-CONTROL DESIGN 
 
In epidemiology, the nested case-control design refers, in practice, to sampling from 
a well-defined cohort (Läärä 2011, Kass 2014). In biostatistics, this design originally 
suggested by Duncan Thomas (1977) refers to a time-matched sampling of controls 
from the risk set (Läärä 2011). Time-matching means here that the controls are 
selected at the time of diagnosis of each new case. Matching fixes the time-scale of 
the study. The subjects in the risk set are at the time of the case’s diagnosis at risk, 
i.e. alive, without the outcome disease, and under follow-up, and fulfilling possible 
further matching criteria. Time-matched sampling is a special case of (incidence) 
density sampling. The controls are randomly sampled without replacement from the 
risk set to a case-control set. Sampling is independent across risk sets, and the 
probability of being selected from the risk set is the same for all control candidates. 
Therefore, a control can be a member of more than one case-control set. As a case is 
at risk until diagnosis, she can serve as a control for one or more cases with an 
earlier date of diagnosis (Greenland and Thomas 1982). There is no need to follow 
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up the exposure history of controls beyond the case’s diagnosis in nested case-
control studies. As the controls are made similar to cases, they do not form a 
representative sample of the full cohort. 
Usually, matching is not solely limited to time of diagnosis. It is possible to 
reduce biases caused by storage and laboratory analyses by matching for storage 
time, number of freeze-thaw cycles and analytic batch (Rundle et al. 2005). Age and 
sex are commonly used in matching. Matching makes the distributions of matching 
variables in controls similar to those in cases. Matching on a strong confounder 
related to exposure increases efficiency and precision, but overmatching on a non-
confounding variable reduces efficiency. Matching makes a case-control study 
vulnerable to missing information due to, for instance, excessively low serum 
volume if there is only one case and/or control per case-control set. The nested case-
control design becomes less flexible when the number of matching variables 
increases. Counter-matching is an efficient approach in nested case-control design to 
assess interaction between a risk factor measured in the full cohort and another risk 
factor measured only in the case-control sample (Langholz and Borgan 1995). 
Exposure odds ratio between cases and controls is the measure of exposure-
disease association in nested case-control design. It is a valid and efficient estimate 
of incidence rate ratio between those exposed and not exposed in the cohort 
(Breslow 2014) and hazard rate ratio (Läärä 2011). Also absolute risks of diseases 
can be estimated from nested case-control studies. For the assessment of co-factors, 
it is necessary that their effects on outcome are estimated among those having 
exposure that is considered causal, e.g. among human papillomavirus positives in 
cervical cancer aetiology. This leads to a missing data problem, unless the exposure 
is a matching variable. One approach is to break matching, to model with 
unconditional logistic regression, and to reduce bias due to confounding, adjusting 
for the matching variables. Another is to analyse with conditional logistic regression 
the case-control sets with at least one case and one control. A third approach, a 
missing-indicator method, a combination of unmatched and matched analysis, has 
been suggested (Huberman and Langholz 1999). Unfortunately, none of these 
approaches is satisfactory under all conditions (Li et al. 2004). 
 The controls can be reused with restrictions as controls for new outcomes of 
interest by applying the likelihood approach or the probability weighting approach 
(Saarela et al. 2008, Støer et al. 2014). A drawback of reuse is that the effects of 
analytic batch, storage time and freeze-thaw cycles will be present. 
For a valid study, not only the study design but also the methods must be valid. 
Matched case-control studies are analysed with conditional logistic regression, 
maximizing conditional likelihood, or proportional hazards regression, maximizing 
partial likelihood. 
2.3.2 CASE-COHORT DESIGN 
 
This design was originally suggested by Ross Prentice (1986). The control group, a 
subcohort, is sampled at the beginning of the follow-up. Sampling is not time-
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matched, which is the key difference between the case-cohort and the nested case-
control design. The subcohort, a simple random sample from the cohort, is used as a 
comparison group for all cases in the cohort. The subcohort is selected without 
regard to disease status. The subcohort provides information about the person-time 
experience in the full cohort. 
 Stratification is a means to increase the efficiency in case-cohort studies. The 
subcohort is selected by applying stratified random sampling. There are two types of 
stratified case-cohort studies, confounder-stratified to deal with confounding and 
exposure-stratified to increase efficiency (Cologne et al. 2012). In confounder-
stratified studies, sampling and modelling strata correspond with each other, and in 
exposure-stratified studies, sampling is stratified, but the model is not (Langholz and 
Jiao 2007). In exposure-stratified studies, exposure is known for the entire cohort, 
and interactions with exposure are of interest. 
Also in case-cohort design, incidence rate ratios and hazard rate ratios are 
estimable (Läärä 2011, Breslow 2014). Furthermore, absolute risks and cumulative 
risk ratios can be estimated (Langholz and Jiao 2007, Breslow 2014). The subcohort 
of the case-cohort study can be used for several diseases and for extended follow-up.  
Case-cohort studies are analysed with proportional hazards regression based on 
weighted exact (or approximate) pseudolikelihood. Analysis of a confounder-
stratified study is a stratified version of an unstratified study. For analysis of an 
exposure-stratified study, a swapper method is recommended (Cologne et al. 2012). 
Case-cohort design is flexibly adapted to fit other kinds of survival models (Petersen 
et al. 2010, Li et al. 2012). 
Control for batch and storage effects and freeze-thaw cycles is more difficult in 
case-cohort design than in nested case-control design. Batch effect will cause bias 
when subsequent case series are investigated in a case-cohort design (Rundle et al. 
2005). 
As an example of the sophisticated use of case-control design, Gilbert and 
Hudgens (2008) developed an approach for measuring principal surrogate 
predictiveness based on case-cohort sampling from a large clinical trial. They 
illustrated the approach assessing HIV-specific immune response to a vaccine as a 
surrogate endpoint for the HIV infection. 
2.3.3 COMPARISON 
 
The case-cohort design has clear advantages over nested case-control design: 
multiple outcomes, less sensitive to missing data, freedom to choose a time-scale, 
more flexible choice of models, sampling of the subcohort and data collection can 
start immediately, subcohort serves also new cases, etc. But, biomarkers tend to 
suffer from lengthy storage, batch effects and freeze-thaw cycles. The nested case-
control design provides simple tools for dealing with such issues and is therefore 
often a more appropriate design for seroepidemiological studies, especially those 
investigating a single outcome. Nested case-control is a low-cost design for which 
standard software is easily available. Choice of design depends on the parameter of 
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interest, aim of the study, data already available (exposure levels for a subcohort or 
cohort), costs, etc. For example, for an aim, risk prediction for a marker, either case-
cohort design or nested case-control design will do, but the latter only if matching is 
not too stringent (Ganna et al. 2012). Finally, it should be kept in mind that the 
principle of random sampling of controls is not necessary in more complex case-
control designs. Of more importance is that ‘the method of control selection must be 
incorporated into the analysis’ (Langholz and Goldstein 2001). 
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3 OBJECTIVES OF THE STUDY 
Longitudinal study designs are needed 
1) to distinguish causes of multiaetiological cervical cancer from confounders or 
mere correlates. 
2) to disclose interactions between different causes or confounders. 
3) to disclose temporal relationships between different causes or confounders. 
 
Study-specific objectives were as follows. 
 
Studies I and III  
To evaluate the joint effects of past infections with the oncogenic and non-
oncogenic HPV types on the risk of subsequent development of cervical 
cancer by applying a nested case-control design on independent materials. 
 
Studies II and III 
To assess the joint effects of past HPV and C. trachomatis infections on the 
risk of squamous cell carcinoma of cervix uteri by applying a nested case-
control design on independent materials. 
 
Study IV 
To investigate the solitary and joint effects of persistent and incident HPV 
and C. trachomatis infections on the risk of developing cervical cancer by 
applying a nested case-control design in a serial setting. 
 
Study V 
To evaluate the order and joint effects of incident and persistent HPV and C. 
trachomatis infections on the risk of developing high-grade cervical 
precancer by applying a stratified case-cohort design in a serial setting. 
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4 MATERIALS AND METHODS 
Efficient and valid study designs, nested case-control and case-cohort design, were 
applied, and analyses were conducted with valid methods. 
 
4.1 STUDY BASES 
Studies I, II and III were the fruit of the collaboration between Finnish, Icelandic, 
Norwegian and Swedish biobanks, cancer registries and laboratories, together 
forming the Nordic Biological Specimen Banks working group on Cancer Causes 
and Control (NBSBCCC). Twelve papers with NBSBCCC study numbers 6, 10, 11, 
13, 14, 16, 20, 21, 22, 23, 26 and 30 were based on the first Cervical Cancer Study of 
the working group (Pukkala 2011). 
The study base for Studies I and II was a joint cohort of approximately 627 000 
women who had donated serum or blood samples to three Nordic population-based 
biobanks in 1974–1994 (Table 1). Most Study I cases and controls were also Study II 
cases and controls, and vice versa. Therefore these studies are referred to as Studies 
I/II in the materials section. 
Study III was the Cervical Cancer Study II of the working group. The study base 
was a joint cohort of four Nordic population-based serum banks to which more than 
900 000 women had donated serum samples during 1973–2002 and contributed to 
follow-up of approximately 15 000 000 woman-years by the end of the year 2002. 
The study base for Study IV consisted of women aged 25–59 years who had 
participated in the population-based cytological screening programme for cancer of 
cervix uteri in Västerbotten county (Sweden) from 1969 to 1995. Women eligible for 
the study had an unoperated cervix and had had at least one cytologically normal 
smear and at least one additional Pap smear. 
The study base for Study V consisted of 94 349 women who had donated to the 
Finnish Maternity Cohort serum samples of two consecutive pregnancies within five 
years and were younger than 32 years in 1992–2004. The women were eligible for 
the study until diagnosis with CIN 3 or ICC, hysterectomy, emigration, death or 
closing date of the study, i.e. 31 December 2004. The women had contributed to 
follow-up of approximately 450 000 woman-years. 
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4.2 SERUM BANKS (I/II, III, V) 
4.2.1 JANUS SERUM BANK (I/II, III) 
 
The Janus Serum Bank was established in Norway in 1973 to store sera collected 
from originally healthy individuals (Jellum et al. 1995, Langseth et al. 2009). The 
Norwegian Cancer Society owned the Janus Serum Bank up to 1 May 2005, after 
which the bank has been overseen by the Cancer Registry of Norway (Gislefoss and 
Jellum 2006). By the end of the year 1992, approximately 144 000 women had 
donated serum samples to the serum bank during regular health examinations, 
particularly in connection with evaluation of risk factors for chronic diseases (Table 
1). The number of female donors was virtually the same in 2003. 
During phase I, covering the period 1974–1978, the study area comprised one 
county from western, central and northern Norway, Sogn og Fjordane, Oppland and 
Finnmark, respectively. During phase II, in 1981–1992, the study area included the 
whole country, except the two southern counties of Buskerud and Hordaland. Most 
of the phase II subjects donated a serum sample in the context of a cardiovascular 
health examination of 40- to 42-year-old Norwegians. The Janus health examination 
donors had a lower cancer incidence than the comparable general Norwegian 
population (Table 1) (Pukkala et al. 2011), but the Janus Serum Bank is considered 
to be representative of the Norwegian population (Langseth et al. 2009). 
For Study III, also another subcohort of the Janus Serum Bank, 14 000 female 
Red Cross blood donors from Oslo, was included. The women were enrolled in 
1973–1991 and 1997–2000. The subcohort is not considered to be representative of 
the Norwegian population (Langseth et al. 2009). 
4.2.2 FINNISH MATERNITY COHORT (I/II, III, V) 
 
The Finnish Maternity Cohort (FMC) serum bank has collected serum samples 
during early pregnancy (first trimester) in order to screen for congenital infections in 
Finland since 1983 (Bardy et al. 1993). The serum samples are drawn at the 
maternity clinics, and almost all (more than 98%) pregnant women have donated 
serum samples to the bank. At the end of 1994, the bank contained serum samples 
from approximately 465 000 women. By 2003, a total of 681 000 women had 
donated about 1.4 million samples to the FMC. The National Institute for Health and 
Welfare (until 2008, the National Public Health Institute of Finland) owns the 
Finnish Maternity Cohort serum bank. An informed consent for the research use of 
samples has been obtained from donors since 2001, and samples donated before 
2001 can be used for medical research according to Finnish law (Kaasila et al. 
2009). 
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Sample pair cohort and subcohort of the FMC (V) 
 
Previously, a cohort of all FMC sample pairs of consecutive pregnancies within five 
years of women, who were aged under 29 years in 1995–2003, at the midpoint of the 
sample withdrawals, had been identified for studies on HPV co-infections and 
population-level competition of HPV types (Kaasila et al. 2009, Merikukka et al. 
2011). The cohort comprised 123 773 sample pairs donated by 97 124 women. It was 
divided to 12 strata by age, <20, 20–22, 23–25 and 26–28 years, and calendar time, 
1995–1997, 1998–2000 and 2001–2003, at the midpoint of the pregnancies. From 
each stratum, 200 or 400 samples were randomly selected for a subcohort of 3600 
sample pairs, which were donated by 3569 women. Serology results for HPV types 
6, 11, 16, 18, 31, 33 and 45 and C. trachomatis were available for the sample pairs of 
the subcohort (Merikukka et al. 2011). 
4.2.3 NORTHERN SWEDEN HEALTH AND DISEASE STUDY (I/II) 
 
The Västerbotten Intervention Programme (VIP) and the Northern Sweden 
MONICA (abbreviation for the Multinational Monitoring of Trends and 
Determinants in Cardiovascular Disease) are population-based sub-banks of the 
Northern Sweden Health and Disease Study Cohort. In 1985, the VIP cohort was 
initiated in a northern Swedish county, Västerbotten (Dillner et al. 1994, Hallmans et 
al. 2003). Each year, all residents aged 40, 50 or 60 years are invited to participate in 
a health-promoting project, including the donation of biological samples for future 
medical research. The participation rate was about 65%. By the end of the year 1994, 
the VIP cohort had received blood samples from 16 500 women. 
The Northern Sweden MONICA project contains material from screenings for 
risk factors of cardiovascular diseases. The first screenings were carried out in 1986, 
1990 and 1994. The screenees come from the counties of Västerbotten and 
Norrbotten. The first screening round was not available for the Cervical Cancer 
Study. The MONICA project received blood samples donated by 1700 women in 
1990 and 1994. Half of the women are also included in the VIP cohort (Pukkala et 
al. 2007). The blood samples of the Northern Sweden Health and Disease Study 
Cohort are stored at the Medical Biobank in Umeå University Hospital. 
4.2.4 NORTHERN SWEDEN MATERNITY COHORT (III) 
 
The Northern Sweden Maternity Cohort has since 1975 collected rubella screening 
samples of pregnant women from Västerbotten county and since the 1980s from a 
larger area, the four northernmost counties in Sweden. In 2003, the virus laboratory 
of Umeå University contained samples of 86 000 women.  
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4.2.5 ICELANDIC MATERNITY COHORT (III) 
 
The Icelandic Maternity Cohort has collected rubella screening samples from Iceland 
since 1980. In 2003, samples of 49 000 women were contained within the 
Department of Medical Virology of Landspitali University Hospital. About 6% of 
the donors have emigrated after serum sampling (Pukkala et al. 2011). Their samples 
and data cannot be used in the studies, as the date of emigration is not available at 
the biobank. 
 
4.3 ORGANIZED CERVICAL CANCER SCREENING 
PROGRAMME IN VÄSTERBOTTEN COUNTY (IV) 
The population-based invitational cytological screening programme for cancer of the 
cervix uteri was started in Västerbotten county in 1969. The screening programme 
was targeted to women 25–59 years of age. Invitations were issued at four-year 
intervals. The attendance rate was higher than 80%. Until the early 1980s, smears 
were taken using a wooden Ayers spatula and a cotton tip applicator. The latter was 
replaced by a cytological brush in the mid-1980s (Cytobrush
®
, Medscand Medical 
AB, Malmö, Sweden). All smears of the screening programme, or obtained outside 
the programme and histological specimens were recorded and stored at one hospital, 
Umeå University Hospital, where all diagnoses based on cytological findings in Pap 
smears were made. 
 
4.4 CANCER REGISTRIES 
The Cancer Registry of Norway, the Finnish Cancer Registry, and the Icelandic 
Cancer Registry are nationwide, and started operating in 1952 in Norway and 
Finland and in 1953 in Iceland, respectively. The nationwide Swedish Cancer 
Registry started operating in 1958. In the late 1970s, cancer registration was 
decentralized in Sweden, and data since 1958 were transferred to six regional cancer 
registries (Association of the Nordic Cancer Registries 2000). The regional cancer 
registries send coded data on an annual basis to the central cancer registry at the 
National Board of Health and Welfare. The regional cancer registry at the 
Oncological Centre in Umeå covers the four northernmost counties in Sweden 
(Association of the Nordic Cancer Registries 2000). All of these registries are 
population-based. Reporting of new cancer cases is compulsory for hospitals, 
physicians and pathology laboratories. In Iceland, reporting of cancer cases was 
voluntary until 2007. The primary basis of registered cancer diagnosis is 
morphology. 
 The coverage of the cancer registries for solid tumours is excellent, close to 
100% (Lund 1981, Mattsson and Wallgren 1984, Teppo et al. 1994). The Norwegian 
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cancer register was 98.8% and 99.97% complete with regard to invasive cervical 
cancer in 1985 and 2001–2005, respectively (Bilet et al. 2009, Larsen et al. 2009). 
The Norwegian cancer register data can be considered almost complete four years 
after the year of diagnosis (Larsen et al. 2007). The Finnish cancer register was 99% 
complete with regard to invasive cervical cancer in 1998–2007 (Lönnberg et al. 
2012b). The Finnish cancer register data are considered a reliable source of 
information for follow-up of cancer incidence in large cohort studies (Korhonen et 
al. 2002). According to Hospital Discharge Registry record linkage, the invasive 
cervical cancer data of the Icelandic cancer register was 100% complete during 
2005–2009 (Sigurðardóttir et al. 2012). In 1998, the Swedish cancer register was 
96% complete according to a sample survey (Barlow et al. 2009). For further details 
of the cancer registries and registration, and other registers see Technical Appendix 
1. 
 
4.5 STUDY DESIGN 
4.5.1 NESTED CASE-CONTROL DESIGN, ONE SERUM SAMPLE (I/II, 
III) 
Case-control design nested in the joint cohort of serum banks was adopted. The 
design was longitudinal, as the biological markers of the putative risk factors for 
invasive cervical carcinoma were identified from prediagnostic sera. The follow-up 
time was maximized by studying the first serum samples donated by the subjects. 
 
 
Identification of cases (I/II, III) 
 
In Studies I/II, the patients eligible to be included in these studies (as cases) were 
diagnosed with invasive carcinoma of the uterine cervix (International Classification 
of Diseases 7th revision code 171) at least 15 days after serum sample donation. 
Cases were identified by linking the data files of the serum banks and the cancer 
registers using personal identification numbers.  
Altogether 196 cases were identified by the linkages. Fourteen cases were 
excluded, four carcinomas in situ, one leiomyosarcoma, three without a reported 
histology, four whose serum sample was postdiagnostic or donated too close to the 
date of diagnosis and two whose serum sample could not be located. The remaining 
182 cases were included in Study I. The follow-up time of the cases was five years 
on average, with a minimum of 15 days, and a maximum of 16 years. There were 
178 ICCs and 148 SCCs in Study II after histological reclassification (for details, see 
Technical Appendix 2). At the time of linkage in 1994, about 120 000 serum samples 
of the Janus Serum Bank were incorrectly labelled. Cases among the donors of these 
samples could not be identified. More than 30 women, who were donors to the 
Health examinations sub-bank of the Janus Serum Bank and were registered as 
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patients with invasive cervical carcinoma before the linkage, could not be identified. 
Donors of 15 000 samples to the FMC could not be identified because of incorrect or 
missing personal identification number. 
In Study III, linkage to national cancer registers identified 653 cases of invasive 
cervical carcinoma diagnosed during 1975–2002. The cases donated the first serum 
sample more than one month before diagnosis. Forty-nine cases were excluded from 
the study, as the sample could not be located or the sample volume was too low (34 
cases), behaviour of the neoplasm was benign or morphology was not reported to the 
cancer register (15 cases). After re-examination of cancer tissues and 
histopathological slides (see Technical Appendix 2), morphologies of the final 604 
cases were squamous cell carcinoma (470 cases), adenocarcinoma (111), 
adenosquamous carcinoma (21) and undifferentiated carcinoma (2). The cases were 
enrolled in the study on average at an age of 31.4 years (range, 15.5–60.4 years) and 
controls at 31.5 years (range, 14.8–59.7 years). The cases were followed for on 
average 9.6 years (range, 3 months–25.5 years) and were on average 41.0 years 
(range, 21.5–70.5 years) at diagnosis. This study does not have any cases in common 
with Studies I/II. 
In comparison with the national reference rates, incidence of cervical cancer was 
significantly lower than expected among donors to the Janus Serum Bank (Table 2). 
Among donors to the maternity cohorts, cervical cancer incidence was close to the 
expected figure. 
 
 
 
 
Matching (I/II, III) 
 
In Studies I/II, for each case, three cancer-free female controls were randomly 
selected, individually matched for age at first serum sampling (±2 years), storage 
time of the first serum sample (±2 months) and area of residence (Finland, Northern 
Biobank SIR (cervival 95% CI2
Study I Study II Study III Study I Study II Study III cancer)2
Janus                     Three counties 80/240 79/237 36/178 40.7/46.7 40.6/46.9 38.6/56.6
Serum                   Several counties 48/144 47/141 130/647 44.7/47.3 44.9/47.5 40.7/47.6
Bank                      Oslo3 –/– –/– 46/228 34.2/45.0  0.75 0.56–0.99
Finnish Maternity Cohort 49/139 48/137 174/854 30.0/34.7 30.1/34.7 28.9/38.4  0.95 0.87–1.03
Northern Sweden Health      VIP4 4/12 3/9 –/– 49.2/51.1 46.6/47.9  0.72 0.47–1.06
    and Disease Study     MONICA5 1/3 1/3 –/– 56.7/57.0 56.7/57.0 1.48 0.48–3.46
Northern Sweden –/– –/– 115/573 26.6/37.1  0.97 0.82–1.14
    Maternity Cohort
Icelandic Maternity Cohort –/– –/– 103/500 25.7/34.4  1.01 0.84–1.18
1Cases' mean age; 2Amended from Pukkala et al. (2007, 2011), national reference rates, closing year for SIR estimation: Norway 2001, Finland
  and Iceland 2005, Sweden 2003; 3Red Cross blood donors; 4Västerbotten Intervention Programme; 5Multinational Monitoring of Trends and
  Determinants in Cardiovascular Disease
No. of cases/controls Age1 at serum sampling/diagnosis
 0.82 0.75–0.90
Table 2. Study-specific numbers of cases and controls and cases' mean age at serum sampling and diagnosis, and standardized
incidence ratio (SIR) and 95% confidence interval (CI) for cervical cancer, by biobank and sub-bank.
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Sweden and Norway), and in Norway for county. The alive status of the control 
candidates at the time of case diagnosis was probably not checked for in all centres. 
If three controls for a case could not be found, the matching criteria on age and 
storage time were widened. The age at serum sampling of six controls differed by 
more than four years from that of the case, and difference in storage time was never 
greater than six months. The serum samples of eight controls could not be located. 
Finally, there were 182 cases and 538 controls for Study I, and 178 cases and 527 
controls for Study II (Table 2). 
In Study III, five female controls were individually matched to a case. Age at 
serum sampling (within two years), storage time (within two months), area of 
residence (Finland, Iceland, Northern Sweden and Norway) and in Norway, county 
and blood donor status were individually matched for. The matching criteria on age 
and storage time were widened if the number of control candidates was insufficient. 
The final material comprised 604 cases and 2980 controls.  
4.5.2 NESTED CASE-CONTROL DESIGN, TWO SMEARS (IV) 
 
 
Identification of cases 
 
Linkage between the cytology registry and the regional cancer registry at the 
Oncological Centre in Umeå identified 133 eligible women, whose smear taken 
before diagnosis with invasive cervical carcinoma was normal. Four of them had 
incorrect entry in the cancer registry and 11 had non-invasive cervical neoplasia. 
After theses exclusions, 118 cases with ICC remained. 
 
 
Matching 
 
Women eligible to be controls did not develop ICC before the time-point of 
diagnosis of the corresponding case. For each case, one control was matched for age 
(same calendar year of birth) and time-point of sampling of the baseline smear. The 
average age when the prediagnostic Pap smear was taken was 44.2 years (range, 
19.1–74.1 years) among the cases and 44.1 years (range, 19.5–74.4 years) among the 
controls. The date of smear taking differed 1 month on average. The mean time 
between the sampling of the baseline smear and cancer diagnosis was 5.6 years 
(range, 0.5 months–26.2 years). The controls were required to have been followed up 
beyond the date of diagnosis of the corresponding case. The control’s normal smear 
immediately after the date of diagnosis was chosen. The time-point of cancer biopsy 
and the second normal smear of the control differed on average by 9.6 months. 
Frequency matching was applied to increase statistical efficiency. Matched pairs 
were pooled so that 118 matched pairs reduced to 74 strata. In each stratum, there 
were 1 to 5 cases and the same number of controls. Those strata were available for 
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analyses of baseline smears. One hundred and four cases and controls in 70 strata 
were available for analyses of baseline smears, second smear and cancer biopsy. 
4.5.3 CASE-COHORT DESIGN, TWO SERUM SAMPLES (V) 
 
 
Conversion of the sample pair cohort into the study cohort 
 
A case-cohort design was adopted to investigate the order of infections and risk of 
high-grade cervical precancer. The sample pair cohort and the subcohort of the FMC 
were not as such eligible for a study with incidence of cervical precancer as the 
outcome. In this study, cohort members were women instead of sample pairs. 
Follow-up of a given woman for cervical precancer started at the beginning of the 
month directly after the date of the second serum withdrawal. To be at risk during 
follow-up, a woman must not have emigrated from Finland, needed to have a Finnish 
personal identification number and cervix uteri without a former diagnosis of 
cervical precancer or cancer. In other words, follow-up ended at diagnosis with 
cervical precancer or just before censoring due to hysterectomy, emigration, 
diagnosis with cervical cancer, death or the common closing date of 31 December 
2004. For studies with incidence of cancer or precancer as outcome, time since the 
serum withdrawal until diagnosis is usually maximized, i.e. the first sample pair of a 
given woman was preferred. 
A starting point for a cohort was the 97 124 women of the sample pair cohort and 
their records related to the first sample pair. A total of 2385 women were excluded 
because they had donated the second serum sample in December 2004 or later. 
According to the linkage to the cancer register, 347 women had to be excluded 
because they were diagnosed with cervical precancer or cancer before (or during the 
same month and year) donating the second serum sample. Linkage to the Population 
Information System (for details of the register, see the Technical Appendix 1) 
revealed that 42 women had emigrated before the second serum sampling, and thus, 
were excluded (they could not be followed for CIN 3/AIS during their stay abroad). 
One woman was excluded, as her samples were not withdrawn within five years.  
The final cohort size was 94 349 women. The subcohort size decreased mainly due 
to exclusion of the second and third serum sample pairs from 3569 women to 2796 
women. The first and second available/eligible samples were not necessarily related 
to the woman’s first and second pregnancy. A third of the cohort members reported 
at the maternal welfare clinic that the pregnancy is the third or later in connection 
with donating the second serum sample of the sample pair. About 13% of the women 
had given birth to at least two children before withdrawal of the second serum 
sample. 
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Identification of cases 
 
Linkage of the Finnish Maternity Cohort and the Finnish Cancer Registry, permitted 
by the Ministry of Health, identified 516 cervical precancer or cancer cases 
diagnosed after the second serum sampling by the end of the year 2004. One case 
had emigrated before diagnosis, and was excluded before emigration. There were 
490 cases, of whom 474 had CIN 3 and 16 AIS diagnosis. Twenty-three were 
members of the subcohort and were included in the analysis. Twenty-five women 
were diagnosed with invasive cervical carcinoma. Among the FMC donors, the SIR 
for CIN 3/AIS was 1.07 (1.04–1.09) (Pukkala 2011). Closing year of the estimation 
was 2005. 
 
 
Follow-up of the study cohort 
 
Finally, the study cohort was linked to the care register for hysterectomies (for 
details, see Technical Appendix 1). Follow-up of 490 women ended at diagnosis 
with CIN 3/AIS or due to censoring just before the closing date (93 387 women), 
hysterectomy (261 women), emigration (96 women), death (90 women) or diagnosis 
with invasive cervical carcinoma (25 women). The women were followed on 
average for 4.8 years, and the average time between sample withdrawals was 2.4 
years. Thus, there was an average of six years since a possible seroconversion until 
the end of follow-up. Total follow-up time in the full cohort was approximately 
450 000 woman-years. 
 
 
Strata 
 
The case-cohort design was confounder-stratified. In other words, stratification 
variables were confounders, and the sampling strata corresponded to the model 
strata. The strata were defined by age and calendar period at the midpoint of 
consecutive pregnancies, and in most of the material the pregnancies were the 
woman’s first and second. The range of stratum-specific numbers of cohort members 
was 1746–18 936 and of subcohort members 140–366. The range of sampling 
fractions was 0.02–0.11. There were 1 to 140 cases per cohort stratum. 
 
4.6 LABORATORY METHODS 
4.6.1 SEROLOGY (I/II, III, V) 
 
All serological analyses were performed on coded specimens. 
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HPV serology (I/II, III, V) 
 
Immunoglobulin G (IgG) antibodies specific for oncogenic types (16 and 18, and in 
Studies I/II and V 33, and in Study V 31 and 45) and non-oncogenic types (6 and in 
Studies I/II 11) of HPV were determined by a standard ELISA using baculovirus-
expressed HPV capsids (Kirnbauer et al. 1994). VLPs were kindly provided by Drs. 
B. Colau and F. Dessy (GlaxoSmithKline Biologicals, Rixensart, Belgium), Dr. J. 
Dillner (Karolinska Institute, Sweden), Dr. K. Jansen (Merck Research Laboratories, 
Philadelphia, PA) and Dr. R. Kirnbauer (University of Vienna, Austria). The cutoff 
levels for seropositivity had been validated in previous studies (Dillner et al. 1997, 
Silins et al. 1999, Laukkanen et al. 2003). 
In Study V, the first and second subcohort samples were analysed for HPV16 at 
different times. Due to a technical error in the analyses, the HPV16 results of the 
first samples were excluded. The second serum samples of cases and subcohort 
members were analysed for HPV16 at the same time. The case and subcohort 
samples were analysed for the other HPV types at different times, and assay drift 
was imminent. The interval, (cut-off level − standard deviation, cut-off level + 
standard deviation) was considered a grey zone. The standard deviation was 
calculated for the absorbance values below cut-off level. Absorbance value below or 
above the grey zone was considered seronegative or seropositive, respectively. For 
further details of the grey zones, see Technical Appendix 3. Seroconversion was 
observed, if the first sample was seronegative and the second one seropositive. Two 
infections were considered overlapping and/or virtually concomitant if their 
seroconversions were observed between the first and second serum samplings. 
 
 
C. trachomatis and HSV-2 serology (I/II, III, V) 
 
In Studies I/II, IgG antibodies specific for C. trachomatis were determined by the 
microimmunofluorescence method (Wang and Grayston 1970). Elementary bodies 
of serovar pools B-group (B-E-D), C-group (C-H-I-J) and an intermediate group (G-
F-K) were used as antigens (Washington Research Foundation, Seattle, WA). In 
Studies III and V, IgG antibodies were determined by a major outer membrane 
protein-derived peptide ELISA using a commercial kit (Labsystems, Helsinki, 
Finland) (Anttila et al. 2001). Titres of 1 to 16 or more were considered positive for 
C. trachomatis. 
In Study II, a commercially available HSV-2 glycoprotein G-2 ELISA (Biokit 
SA, Barcelona, Spain) was used to determine IgG antibodies to HSV-2 according to 
the manufacturer’s recommendations. 
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Cotinine serology (I/II, III) 
 
Serum cotinine was measured by radioimmunoassay in Studies I/II (Parish et al. 
1995). Cotinine measurements by radioimmunoassay and gas chromatography are in 
good agreement, although for samples containing high levels of cotinine 
radioimmunoassay tends to give higher results (Anderson et al. 1991). A serum 
cotinine level of 20 ng/mL and above was considered to indicate active smoking. In 
Study III, cotinine was measured using a competitive semiquantitative immunoassay 
method (OraSure Technologies, Bethlehem, PA). The correlation between the results 
of this and the gas chromatometric method was 95% across the range of 0–20 ng/mL 
(Boffetta et al. 2006). The cotinine levels were categorized into groups, less than 20 
ng/mL for non-smokers or persons passively exposed to tobacco smoke, 20–100 
ng/mL for light smokers and >100 ng/mL for heavy smokers (Kapeu et al. 2009). 
4.6.2 DNA MEASUREMENT (II, III, IV) 
 
 
HPV DNA measurement (II–IV) 
 
In Study II, DNA was extracted from formalin-fixed, paraffin-embedded biopsy 
specimens containing cancer lesions from 133 cervical cancer cases (Sigstad et al. 
2002). Six cases were excluded from the HPV-PCR because the quality of DNA 
extracts was not sufficiently good. In Study III, biopsies without CIN 3 or ICC and 
non-amplifiable, beta-globin gene-negative biopsies were excluded from the DNA 
analysis. In Study IV, DNA was extracted from Pap smears and biopsies using 
methods described by Chua and Hjerpe (1995, 1996) and Wallin et al. (1999). The 
diagnostic biopsy was eligible for PCR analysis in Study IV only if the paraffin 
block contained cancer lesions. An empty paraffin block was sectioned between each 
biopsy specimen to prevent cross-contamination. Knives were changed or the 
microtome cleaned thoroughly between each biopsy. In Study IV, PCR using human 
ribosomal gene S14 primers was used to test the quality of the DNA extracts. 
The biopsies were tested for HPV DNA by PCR using the GP5+/6+ primer 
system (de Roda Husman et al. 1995, Jacobs et al. 1997). In Study II, specimens 
were typed with E6- and E7-derived, type-specific primers for HPV types 16, 18 and 
33 (Lie et al. 1999). In Study III, 13 hrHPV types were measured by enzyme 
immunoassay and reverse dot blot hybridization (Söderlund-Strand et al. 2005) or a 
multiplex fluorescent bead–based assay (Schmitt et al. 2006). In Study IV, HPV 
types 16 and 18 were measured by type-specific PCR and types 16, 18, 31, 33 and 73 
by DNA sequencing (Wallin et al. 1999). 
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Chlamydia trachomatis DNA measurement (IV) 
 
PCR analysis for Chlamydia trachomatis was performed using a COBAS 
AMPLICOR
TM
 CT test (Roche Molecular Diagnostics, Branchburg, NJ) with 
primers common to all serovars of C. trachomatis. Positive results were measured 
according to the manufacturer’s instructions, including negative and positive 
controls. The test is highly sensitive and reproducible (Vincelette et al. 1999). PCR 
analyses were performed blinded to case-control status. 
 
4.7  STATISTICAL ANALYSES 
4.7.1 REGRESSION 
 
 
Asymptotic logistic regression (I, II, III) 
 
Exposure odds ratios were estimated by conditional logistic regression with EGRET 
software (Statistics and Epidemiology Research Corporation, Seattle, WA) in Study 
I, GLIM 4 software (Numerical Algorithms Group, Oxford, UK) in Study II and 
SAS version 9.1 software (SAS Institute Inc., Cary, NC) in Study III (Breslow and 
Day 1980). These are valid and efficient estimates of incidence rate ratios and 
hereafter will be referred to as rate ratios (RRs). The 95% confidence intervals (CIs) 
for the RRs were based on a Wald-type statistic in Study I and on profile likelihood 
in Study II (Nelder 1990). The RRs for HPV16 in strata containing incomplete case-
control sets were estimated by unconditional logistic regression in Study II. In Study 
III, the 95% confidence limits for parameters of the conditional analyses were based 
on a Wald-type statistic and those of the unconditional analyses on profile 
likelihood. 
The RRs were adjusted for other HPV types, smoking indicated by high levels of 
serum cotinine, and C. trachomatis in Study I and also for HSV-2 in Study II. In 
Study III, models were adjusted for HPV16, HPV18, C. trachomatis and cotinine. 
Analyses restricted to strata, HPV16 seronegatives, HPV16 seropositives, HPV18 
seronegatives, HPV18 seropositives, were conducted by unconditional logistic 
regression adjusting the RR estimates for the other hrHPV, cotinine and matching 
variables, year of age, calendar year, country, county of Norway and Norwegian Red 
Cross blood donor status. 
A model (1) with HPV16 and a model (2) with different parameters for the effect 
of HPV16 in the absence and the presence of a possible effect modifier, HPV 6 or 11 
(6/11), were used to test for effect modification in Study I. No independent effect on 
risk was assumed for the effect modifier in model 2. The difference between the 
likelihood ratio statistics related to the hierarchical models 1 and 2 with one degree 
of freedom served as a test statistic for effect modification. 
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Exact logistic regression (IV) 
 
Exposure odds ratios and 95% confidence intervals were estimated by exact 
conditional logistic regression with LogXact 4 software (Cytel, Cambridge, MA). As 
valid and efficient estimates of incidence rate ratios, they are referred to as rate 
ratios. If the conditional likelihood function could not be maximized in estimation of 
the point estimates, the less reliable median unbiased estimates were reported (Hirji 
et al. 1989). The confidence intervals are guaranteed to have at least 95% coverage 
for the point estimate. 
  
 
Proportional hazards regression (V) 
 
Rate ratios (RRs) and variances were estimated fitting pseudolikelihood by a Cox 
model with different strata-specific baseline hazards using SAS version 9.2 (SAS 
Institute Inc, Cary, NC) and macros written by Bryan Langholz (Langholz and Jiao 
2007). Model strata corresponded to the sampling strata. Subcohort members, both 
cases and non-cases, enter at the beginning of the month immediately after second 
serum withdrawal and exit just before actual exit time as censored observations. 
Cases, both subcohort and non-subcohort, enter just before diagnosis and exit at 
diagnosis. Thus, subcohort cases contribute two rows to the analytic data set. Non-
subcohort cases contribute to the study only at diagnosis. The pseudolikelihood 
method used exact pseudolikelihood estimator (Langholz and Jiao 2007). The 
estimator is score-unbiased, i.e. conditional expectation of the score from the 
estimator is zero. Simulation studies have shown that the estimator has optimal 
small-sample properties (Cologne et al. 2012). The estimator adjusts biased 
sampling due to over-sampling of cases. Both asymptotic variances based on the 
pseudo-score and robust ‘sandwich’-type variances were estimated. The variance 
estimators are asymptotically equivalent (Langholz and Jiao 2007). Confidence 
(95%) intervals based on the asymptotic variance were reported, although those 
based on robust variance were also valid in this study. The confidence intervals 
based on the robust variance tended to be narrower. HPV16 seropositivity at the 
second serum sample was adjusted. 
4.7.2 INTERACTION ANALYSES (I, II, III) 
 
Statistical interaction of two risk factors requires departure from additivity in their 
effect on outcome (Berrington de González and Cox 2005). A specific type of 
interaction does not occur if the separate effects of the risk factors combine 
additively. The two most popular types of statistical interactions are additive 
interaction and multiplicative interaction. Studying multiplicative interaction is 
equivalent to studying additive interaction on the logarithmic risk scale. Statistical 
interaction is a non-additivity (Berrington de González and Cox 2007). 
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For simplicity, let us assume that two risk factors, X and Z, have two possible 
values, exposed (x and z) and not exposed (‾x and ‾z), respectively. In an additive 
model, the excess rate ratio for the additive joint effect is a sum of excess rate ratios 
for exposure to X in the absence of exposure to Z and for exposure to Z in the 
absence of exposure to X: RRxz – 1 = (RRx‾z − 1) + (RR‾xz – 1). Adding 1 to both sides 
gives the rate ratio for additive joint effect 
(1) RRxz = RRx‾z + RR‾xz – 1.  
When studying the additive interaction, this is the expected RR for the additive joint 
effect to be compared with the observed RR for the joint effect. For brevity, it will 
be called expected additive RR. 
In a multiplicative model, the rate ratio for the multiplicative joint effect is a 
product of rate ratios for exposure to X in the absence of exposure to Z and for 
exposure to Z in the absence of exposure to X, RRxz = RRx‾z RR‾xz. When studying the 
multiplicative interaction, this is the expected RR for the multiplicative joint effect to 
be compared with the observed RR for the joint effect. For brevity, it will be called 
expected multiplicative RR. The rate ratios in the product above are solitary or 
separate effects. 
A positive deviation from the expected joint effect indicates that exposures 
intensify each other’s effects on the risk of disease, i.e. they act synergistically on 
the risk of disease. A negative deviation indicates that the exposures diminish each 
other’s effects on the risk of disease, i.e. they act antagonistically on the risk of 
disease. When there is no deviation, the exposures act independently on the risk of 
disease. 
The confidence limits for the expected additive RR were approximated by the 
delta method on the RR estimates. The confidence limits for the expected 
multiplicative RR were approximated by the delta method on the logarithms of the 
RR estimates. The P value for testing the null hypothesis, no additive interaction, 
against the alternative hypothesis, additive interaction, was obtained from 
standardized normal distribution using the difference between the observed and 
expected RRs for the joint effect divided by the standard error of the difference as a 
test statistic for a two-sided test. In Study III, additive interaction was detected by 
relative excess risk due to interaction and 95% CI, which were estimated according 
to Hosmer and Lemeshow (1992). Testing the null hypothesis, no multiplicative 
interaction of exposures, against the alternative hypothesis, multiplicative interaction 
of exposures, was carried out with likelihood ratio test to compare two nested 
models, one for the main effects only and the other including also an interaction 
term, by considering the difference between the model-specific scaled deviances. 
In the model for estimation of the observed joint effect of two binary exposure 
variables X and Z on the risk of cervical neoplasia, there was always a variable with 
four categories, a reference category of no exposure to X and Z, a category of 
exposure to X and no exposure to Z, a category of no exposure to X and exposure to 
Z and a category of exposure to both X and Z. Variables to be adjusted were included 
in the model. The expected values for assessing additive and multiplicative 
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interaction were derived from the same model for estimating rate ratios for cervical 
neoplasia. The model required no a priori choice of the type of interaction to be 
studied. 
Absence of a statistical interaction does not imply that there is no biological 
interaction. Statistical interaction refers to variation in a population measure of 
effect, whereas biological interaction refers to effects in individuals (Pearce and 
Greenland 2014). 
4.7.3 SERIAL SAMPLE ANALYSES (IV, V) 
 
In Study IV, the rate ratios for ICC related to baseline C. trachomatis DNA status 
were estimated by lag time, time from the case’s prediagnostic smear to diagnostic 
biopsy, with lag up to three years as the reference category. The joint effects of 
transient (positive-negative), incident (negative-positive) and persistently positive 
combinations of HPV DNA and C. trachomatis DNA on risk of ICC were studied 
with persistently HPV DNA-negative and C. trachomatis DNA-negative women as 
reference category. 
In Study V, the risk of CIN 3/AIS related to seroconversion of one or two 
infections was evaluated with dual seropositivity at first serum sampling as the 
reference class. Also seropositivity at first sampling of one infection and 
seroconversion related to another infection was compared with a situation in which 
the infections were in the reverse order. The magnitude of risk was illustrated with 
persistently double seronegative women as a reference class. HPV types 18 and 45 
were combined, as observations in some single type categories were lacking and the 
type.wise results did not differ considerably. 
The proportion of missing observations in each analysis was 14% in the 
subcohort and 12% in cases. All laboratory results were missing from 8% of the 
subcohort members and 3% of the cases. 
4.7.4 IMPUTATION (II) 
 
The serum cotinine level of four cases and three controls was missing. The missing 
values of smoking can be imputed (replaced) by 128 different combinations of 
values for smokers or non-smokers. One of the combinations is correct. Rate ratios 
for the joint effects of interest were estimated for the non-imputed data set and for 
the 128 differently imputed data sets. The RR estimate for the joint effect of HPV16 
and HPV6/11 among non-imputed data did not lie within the range of the 
corresponding results from the imputed data sets. It was necessary to impute the 
missing values of smoking. For each participant, whose information about smoking 
was lacking, a subset of more than 20 controls was formed, with age at and year of 
serum sampling centred on those of the participant. A pseudo-random number in the 
range of 0–1 was generated. If the pseudo-random number was smaller than the 
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smoking prevalence in the control subset, the participant received a smoker status. 
Otherwise, the participant was given a non-smoker status. 
4.7.5 CORRECTION FOR MISCLASSIFICATION (I, II) 
 
 
Back-calculation (I) 
 
Non-differential misclassification bias in the RR for the joint effect of HPV16 and 
HPV6/11 was assessed using frequencies of misclassification-corrected joint 
distributions of seropositivity for HPV16 and HPV6/11. Misclassification was 
adjusted by deriving the frequencies by back-calculation. Misclassification-corrected 
joint distributions were calculated using the observed joint distributions of these 
HPV types separately among SCC cases and their controls and assuming different 
levels of probabilities, sensitivity (S16 and S6/11), specificity (W16 and W6/11) and 
cross-reactivity (P16|6/11 and P6/11|16) for the HPV16 and HPV6/11 ELISA methods 
(T16 and T6/11). The cross-reactivity, P16|6/11, is here the probability that a case or 
control is classified as HPV16-seropositive by the T16 method because of antibodies 
induced by HPV6/11 infection. Cases and controls were assumed to have equal 
values of sensitivities, specificities, and cross-reactivities because non-differential 
misclassification bias was considered. 
The following definitions and assumptions were made for the calculations: T6/11 
identifies true HPV6/11-seropositives with sensitivity, S6/11. T6/11 misclassifies true 
HPV6/11-seronegatives as HPV6/11-seropositives with complement probability of 
specificity, 1 − W6/11. T6/11 classifies HPV6/11 seropositivity of HPV16 antibodies 
with cross-reactivity, P6/11|16, equally likely whether or not the HPV6/11 antibodies 
are present. The probabilities of correct and misclassified determination of HPV6/11 
seropositivity are: 
 
 
Pr(observe HPV6/11+ | true HPV6/11+ & HPV16+) = S6/11 + (1 − S6/11)P6/11|16, 
Pr(observe HPV6/11+ | true HPV6/11+ & HPV16–) = S6/11, 
Pr(observe HPV6/11+ | true HPV6/11– & HPV16+) = 1 − W6/11(1 − P6/11|16), 
Pr(observe HPV6/11+ | true HPV6/11– & HPV16–) = 1 − W6/11. 
 
The probabilities for observing HPV6/11 seronegativity given the true or 
misclassification-corrected event are complement probabilities of those given above. 
In the probability formulae for observing HPV16 seropositivity, 6/11 and 16 are 
interchanged in the subscripts. It was further assumed about the tests that T6/11 
succeeds or fails in identification of the HPV6/11 antibodies whether or not T16 
succeeds or fails to identify HPV16 antibodies, and vice versa. It was assumed that 
T6/11 and T16 have equal sensitivity and specificity and that the cross-reactivities 
P6/11|16 and P16|6/11 are equal, but these assumptions are not necessary for the 
calculations. 
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As we are evaluating the joint effect of two HPV types, 16 and 6/11, having two 
levels of seropositivity, seronegative and seropositive, there are four 
misclassification-corrected frequencies of interest: numbers of seronegatives for 
both types, seropositives for type 16 only, seropositives for type 6/11 only, and 
seropositives for both types. All of these frequencies have an effect on all four 
observed frequencies, numbers of seronegatives for both types, seropositives for type 
16 only, seropositives for type 6/11 only, and seropositives for both types, unless S16, 
S6/11, W6/11 or W6/11 is equal to 0 or 1, or P16|6/11 or P6/11|16 is equal to 1. A set of four 
equations has to be solved. On the left-hand side of the equations there is the sum of 
unknown misclassification-corrected frequencies, each of which is multiplied by a 
coefficient in the range of 0–1. The coefficients of each misclassification-corrected 
frequency sum up to 1 in the set of equations. Observed frequencies are on the right-
hand side of the equations. There is one solution because the number of equations is 
equal to the number of unknowns. The coefficients come from 4-by-4 observed-by-
misclassification-corrected matrix. For example, the coefficient of misclassification-
corrected frequency of those HPV16+ and HPV6/11– to calculate the observed 
frequency of HPV16+ and HPV6/11– is a product of conditional probabilities 
assumed to be independent. 
 
Pr(observe HPV16+ & HPV6/11– | true HPV16+ & HPV6/11–) = 
Pr(observe HPV16+ | true HPV16+ & HPV6/11–) • 
Pr(observe HPV6/11– | true HPV16+ & HPV6/11–) = S16W6/11(1 − P6/11|16). 
 
To calculate the misclassification-corrected rate ratio for the joint effect, the set 
of equations of both cases and controls has to be solved for given values of 
sensitivity, specificity and cross-reactivity. The solutions are not acceptable if there 
is a negative misclassification-corrected frequency. In such a case, the combination 
of sensitivity, specificity and cross-reactivity is not possible if the other assumptions 
made are correct. 
An error in the numerical example in the Appendix of Study I has been corrected 
in the Errata. 
 
 
Gold standard (II) 
 
Misclassification of HPV serology was assessed by assuming a gold standard of OR 
for SCC related to HPV16 seropositivity in Study II, as described by Hakama et al. 
(2000). The gold standard, OR = 20, was based on comparable, systematically 
reviewed follow-up studies with PCR-based diagnosis of HPV16 infection (Lehtinen 
et al. 2001). As in those studies, ORs were valid and efficient estimates of incidence 
rate ratios, the gold standard of OR is referred to as the gold standard of RR. All 
acceptable specificity and sensitivity combinations consistent with the observed RR 
given the gold standard of RR were estimated. Cross-reactivity was not considered. 
Sensitivity analyses with RR from 12 to 50 as alternatives to gold standard of RR 
were also carried out. 
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The following set of equations was solved in search of a solution for 
misclassification-corrected frequencies: 
 
n1 = S(n11 + n01) + (1 − W) (n10 + n00) 
n11 = S(n11 + n01) 
n1 = n10 + n11 
n0 = n01 + n00. 
 
Frequencies, n1 and n0, are observed numbers. In the subscript, 1 refers to HPV16 
seropositives and 0 to HPV16 seronegatives. The frequencies with two digits in the 
subscript are unknown. The first digit refers to observed and the second to true 
HPV16 seropositivity status. Thus, 
  
n11 = number of true HPV16 seropositives = n(observe HPV16+ & true HPV16+), 
n10 = number of false HPV16 seropositives = n(observe HPV16+ & true HPV16–), 
n01 = number of false HPV16 seronegatives = n(observe HPV16– & true HPV16+), 
n00 = number of true HPV16 seronegatives = n(observe HPV16– & true HPV16–).  
 
For a given value of sensitivity, S, a value of specificity, W, was numerically solved 
with a precision of up to 0.01%, or vice versa, which resulted in misclassification-
corrected non-negative frequencies of cases and controls and misclassification-
corrected RR of 20. For the analyses, all four observed cell frequencies of the case-
control status-by-HPV16 seropositivity table, sensitivity and specificity were 
required. 
The procedure was repeated in subgroups defined by the other risk factors being 
examined, i.e. in those who were C. trachomatis-seropositive or C. trachomatis-
seronegative, in smokers or non-smokers or in HPV6/11-seropositive or HPV6/11-
seronegative subjects. For graphical presentation, several sensitivity-specificity pairs 
or sensitivity-(1–specificity) pairs on an equipotential curve (for example, RR = 20) 
were calculated.  
Statistical variability was taken into account by repeating the analyses with upper 
and lower 95% confidence interval limits of the estimated RRs and assuming fixed 
marginal frequencies of the 2-by-2 tables describing the association between HPV16 
seropositivity and case-control status in the subgroups defined by measurements for 
C. trachomatis and smoking, or C. trachomatis and HPV6/11. For the analyses, four 
hypothetical cell frequencies of the case-control status-by-HPV16 seropositivity 
table, consistent with the confidence limit, sensitivity and specificity were required.  
Inferences applied to the curves defined by the point estimates of RRs and the 
areas of admissible values defined by confidence intervals of RRs were similar. Any 
combination of specificity and sensitivity of the HPV16 antibody assay common to 
the subgroups, C. trachomatis seronegative and -positive or HPV6/11 seronegative 
and -positive, was taken as an indication of the possibility of non-differential 
misclassification bias to account for the observed interactions.  
Differential misclassification of HPV16 serology due to C. trachomatis or 
HPV6/11 could have taken place if there were non-identical different subgroup-
Materials and methods 
60 
specific combinations of sensitivity and specificity of HPV serology consistent with 
the difference between the estimated RR and the gold standard. A true interaction 
was regarded as a plausible explanation only if no combination of sensitivity and 
specificity of HPV serology could account for the difference between the observed 
RR and the gold standard, and if the assumed value of the gold standard is correct. 
However, it is possible that differential misclassification bias other than the type 
described above could account for the difference between the observed RR and the 
gold standard. 
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5 RESULTS 
The main focus of this thesis is the joint effects. Three types of joint effects on risk 
of developing cervical neoplasia were studied. First, the joint effects of different 
human papillomaviruses, second, the joint effects of human papillomaviruses and 
Chlamydia trachomatis, and, third, the effects related to the order of these infections 
as compared with their reverse order, and other reference groups were investigated. 
 
5.1 JOINT EFFECTS OF DIFFERENT HPVS ON RISK OF 
DEVELOPING CERVICAL NEOPLASIA 
In Study I, the joint effects of prediagnostic type-specific HPV seropositivities on the 
risk of cervical neoplasia were smaller than expected on a multiplicative basis. The 
joint effect of seropositivity to HPV16 and HPV6/11 was antagonistic both for ICC 
and SCC. While the corresponding expected multiplicative RRs were 5.4 and 12, the 
observed RRs: for ICC 0.7 (95% CI, 0.2–2.5) and for SCC 1.0 (95% CI, 0.3–4.0), 
were significantly lower. All of the misclassification-corrected estimates (applying 
different levels of sensitivity, specificity and cross-reactivity for HPV serology) for 
SCC were more antagonistic. In addition to the hypothesis of no deviation from the 
multiplicative joint effect (no multiplicative interaction), another hypothesis, no 
effect modification by HPV6/11 was also rejected, and the antagonistic interaction 
was verified. The hypothesis, no multiplicative interaction, was also rejected in case 
of the antagonistic joint effects of HPV16 and HPV18 seropositivity on ICC and 
SCC risk and HPV16 and HPV33 seropositivity on SCC risk. 
Also after re-examination of histology, in Study II, the joint effect of 
seropositivity to HPV16 and HPV6/11 on SCC risk was antagonistic. The RR of the 
observed effect of joint seropositivity was 1.1 (95% CI, 0.3–3.1), while the expected 
multiplicative RR was 8.7 and additive RR 5.3. Furthermore, although the joint 
effect of HPV16 and HPV6/11 on the risk of HPV16 DNA-positive SCC was 
slightly increased (RR, 1.9; 95% CI, 0.4–7.8), the hypothesis of no multiplicative 
interaction was again rejected, and the HPV16 and HPV6/11 antagonism verified. 
In Study III, the RR for the joint effect of HPV16 and HPV6 seropositivity was 
increased, 2.4 (95% CI, 1.7–3.4), but it was significantly smaller than the expected 
multiplicative RR, 5.8. The estimate of relative excess risk due to interaction 
suggested a negative additive interaction, i.e. antagonism. There was neither 
increased nor decreased risk of HPV16 DNA-positive ICC among HPV18 
seropositives. This was true also for HPV18 DNA-positive ICC among HPV16 
seropositives. 
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5.2 JOINT EFFECTS OF HPVS AND CHLAMYDIA 
TRACHOMATIS ON RISK OF DEVELOPING 
CERVICAL NEOPLASIA 
In Study II, the joint effect of HPV16 and C. trachomatis seropositivity on the risk 
of SCC was antagonistic. The hypotheses of no multiplicative interaction and no 
deviation from the additive joint effect (no additive interaction) between HPV16 and 
C. trachomatis were rejected in both the SCC and HPV16 DNA-positive SCC 
materials. Neither among C. trachomatis seropositives nor among HPV6/11 
seropositives no combinations of sensitivity and specificity in the HPV16 antibody 
assay could account for the difference between the observed 0.6-fold HPV16-
associated RRs and gold standard RR = 20. The C. trachomatis-associated RR was 
significantly increased among HPV16 seronegatives both for SCC and for HPV16 
DNA-positive SCC. 
In Study III, the Chlamydia trachomatis-associated risk of SCC was significantly 
increased among HPV18 seropositives (RR, 2.1; 95% CI, 1.2–3.7), but not among 
HPV16 seropositives (RR, 1.2; 95% CI, 0.8–1.8). The RR for joint effect of 
seropositivity to HPV16 and Chlamydia trachomatis on the risk of SCC was 
increased, 4.7 (95% CI, 3.3–6.7), but smaller than the expected multiplicative RR, 
9.5. The joint effect of HPV18 and C. trachomatis on the risk of SCC was 
multiplicative, the observed and expected multiplicative RRs were equal to 2.8 
(Table 3). Seropositivity for HPV18 was associated with significantly increased risk 
of SCC only if the women were also seropositive for C. trachomatis. 
 
 
 
 
 
 
 
Table 3. Adjusted1 rate ratios (RRs) and 95% confidence intervals (CIs) for squamous cell
carcinoma of the cervix uteri in relation to seropositivity for HPV18 and/or C. trachomatis 
in a cohort of more than 900 000 women who donated serum samples to Nordic biobanks 
in 1973–2002.
RR 95% CI
HPV18 C.trachomatis Cases Controls
Seronegative Seronegative 197 1413 1
Seronegative Seropositive 163 527 1.9 1.5–2.5
Seropositive Seronegative 31 129 1.4 0.9–2.2
Seropositive Seropositive 58 91 2.8 1.9–4.1
1Adjusted for HPV16 and cotinine.
Seropositivity for Number of
 63 
In Study IV, clearance of HPV DNA and/or C. trachomatis DNA positivity, as 
compared with persistent HPV DNA and C. trachomatis DNA negativity was non-
significantly associated (RR, 15; 95% CI, 0.8–1500) with the risk of ICC (Table 4). 
Incident infection with either HPV or C. trachomatis by diagnosis was highly 
significantly associated with increased risk of ICC (RR, 110; 95% CI 17–4900). 
Persistent DNA positivity including subsequent/concomitant DNA positivity for 
HPV and/or C. trachomatis by diagnosis was extremely significantly associated with 
increased risk of ICC (RR, 220; 95% CI, 21–15 000). There were not enough C. 
trachomatis DNA-positives for a more detailed study of the joint effects. 
 
 
 
 
 
In Study IV, the HPV DNA-adjusted RR, 17, for ICC associated with C. 
trachomatis DNA in prediagnostic smear was statistically significant, 95% CI (2.6–
∞). Nine out of ten C. trachomatis DNA-positive cases at prediagnostic smear-taking 
were HPV DNA-negative. All of the controls were C. trachomatis DNA-negative. C. 
trachomatis DNA positivity was associated with long and HPV DNA positivity with 
short lag between the prediagnostic smear and cancer diagnosis. None of the cases 
were C. trachomatis DNA-positive in both smear and cancer biopsy.  
 
5.3 ORDER OF DIFFERENT CARCINOGENS IN THE 
DEVELOPMENT OF CERVICAL NEOPLASIA 
In Study V, paired prediagnostic (CIN 3) serum samples from a sizeable case-cohort 
material were analysed for HPV and C. trachomatis antibodies. The risk for CIN 
3/AIS was very high (RR, 28; 95% CI, 4.3–190) among women who were infected 
with and seroconverted for C. trachomatis and HPV18/45 within approximately 2.4 
Table 4. Rate ratios (RRs) and 95% confidence intervals (CIs) for invasive cervical carcinoma in relation
to the presence of HPV DNA or C. trachomatis  DNA in prediagnostic cytological smears or cervical 
biopsies donated by Swedish women from Västerbotten county in 1969–1995.
RR2 95% CI
Prediagnostic phase Diagnostic phase Cases Controls
smear biopsy/smear1
Both negative Both negative 19 98 1
One or both negative Both negative 4 2 15 0.8–1500
Both negative One or both negative 46 3 110 17–4900
One or both negative One or both negative 35 1 220 21–15 000
1Case: diagnostic phase biopsy; Control: smear taken after the case's biopsy.
2Exact conditional logistic regression, frequency-matched.
HPV DNA and C. trachomatis  DNA positivity Number of
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years and on average 6 years before diagnosis, as compared with women 
seropositive for C. trachomatis and HPV18/45 already at first serum sampling. Their 
risk was even higher (RR, 96; 95% CI, 15–610) as compared with women 
seronegative for all three infections at both samplings. 
The risk for CIN 3/AIS associated with persistent HPV6 seropositivity before 
HPV31 seroconversion was low (RR, 0.4; 95% CI, 0.0–4.4) compared with women 
seropositive for both HPV6 and HPV31 already at first serum sampling. By contrast, 
the risk associated with persistent HPV31 seropositivity before HPV6 
seroconversion was high (RR, 10; 95% CI, 1.8–57). The RR related to HPV6 
seropositivity before HPV31 seroconversion compared with HPV31 seropositivity 
before HPV6 seroconversion was very low, 0.04, and highly significant (95% CI, 
0.003–0.7). 
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6 DISCUSSION 
The objectives of this PhD thesis are in line with the original registered objectives 
for the doctoral thesis of 24 August 1998. The manuscript of Study I on the 
antagonistic joint effect of past infections with the oncogenic and non-oncogenic 
HPV types on risk of subsequent development of invasive cervical cancer was 
already available, as was the plan for a larger study (III). Study III was initiated to 
gain more power for stratified and interaction analyses. One of the objectives of 
Study III was to investigate whether the new finding, benign HPV infections 
protecting against invasive cervical carcinoma, would emerge again in an 
independent material. 
The joint effect analyses of past HPV and C. trachomatis infections on the risk of 
invasive cervical cancer for Study II were ongoing at the time of the thesis 
registration. The original study plan covered two studies utilizing nested case-control 
design in a serial setting, one for evaluating the effects of incident and persistent 
HPV infections over time and the other the solitary and joint effects of incident 
infections with different HPV types on risk of developing CIN 3+. Studies IV and V 
concentrated not only on HPVs but on the joint effects of hrHPVs and C. 
trachomatis in a longitudinal/serial sample setting. The case-cohort design was 
introduced to Study V, as compared with nested case control design in the original 
plan, to better fulfill the original objectives.  
The study bases represent Nordic women over four decades (1973–2004), but 
only the years 1992–1994 were common to all studies. Thus, the population-based 
nature of the utilized biobanks, except for the Red Cross blood donors from Oslo, a 
sub-bank of the Janus Serum Bank, was important. According to standardized 
incidence ratios, among the biobank donors the incidence of cancer of all sites 
combined was not higher than among a comparable group in the national population 
with the same age and gender distribution by calendar time. This means that the 
study bases represent a healthier portion of the target populations. 
Representativeness of the study base to the target population is, however, not 
necessary for studies with a scientific objective of understanding a phenomenon 
(Rothman et al. 2013, Ahrens et al. 2014). Three maternity cohorts contributed to the 
studies. Only a small proportion of pregnant women did not donate pregnancy-
related serum samples to the maternity cohorts. Also the other biobanks stored 
serum/blood samples from projects in which participation was high. In each study, 
all or the majority of women were of reproductive age at the time of the first serum 
sampling or smear-taking. The population-based cytological screening programme of 
Västerbotten was optimal for Study IV, as all of the smears and histological 
specimens were recorded and stored in one place. 
Most biobanks stored serum samples in –20˚C or –25˚C. Gislefoss et al. (2009) 
reported that immunoglobulin G is relatively stable in the Janus Serum Bank 
material and observed a non-significant difference in IgG concentrations with 
respect to storage time. 
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The Nordic cancer registries are nationwide and registration of invasive cervical 
carcinoma is complete or almost complete. The primary basis of diagnosis is 
morphology, and almost all invasive cervical carcinomas are morphologically 
verified. In the Finnish cancer register, CIN 3 registration is 80% complete. In 
Studies II–IV, histological slides and/or cancer tissues were re-examined for 
confirmation of cancer diagnosis. This made histology more comparable between the 
countries and over the long study periods. Unfortunately, Icelandic legislation 
forbade exporting the slides and tissues. 
Linkages between cancer registers and biobanks and other registers were done 
utilizing unique personal identification numbers. The most remarkable obstacle to 
linkage for Studies I/II was that the cases among donors of 120 000 (28%) Janus 
Serum Bank samples could not be identified due to incorrect labelling. In Study III 
material, there are 34 SCC cases from the Janus health examinations sub-bank, with 
diagnoses made before the year 1992. We checked whether moving the matched sets 
of these cases to Study II material would cause major changes in the joint effect 
results of Studies II and III. Only minor changes in the estimates were observed. 
During follow-up all women had to be at risk of developing invasive cervical 
carcinoma or, in Study V, CIN 3/AIS. As almost all cases were of working age at 
diagnosis, mortality among the controls before the case’s diagnosis was rather low. 
In Studies I/II, it was not necessarily checked in all countries whether controls were 
alive or had emigrated before the case’s diagnosis. Emigrated Icelandic women did 
not contribute to Study III, as the date of emigration was not available at the 
biobank. In Studies I/II and III, we did not check whether women had unoperated 
cervix uteri. In Study IV, women whose cervix uteri were operated did not contribute 
to the control series. This is reasonable, as the controls had to be at risk beyond the 
case’s diagnosis. In Study V, women were at risk until the event which occurred 
first, diagnosis with CIN 3/AIS or ICC, death, emigration, hysterectomy or end of 
study at a common closing date. Studies I/II were based on the largest follow-up 
study incidence of invasive cervical carcinoma as outcome in the 1990s (Dillner et 
al. 1997). Study III was more than threefold larger than Studies I/II, with a twofold 
longer average follow-up time of almost ten years. 
Age at serum sampling or baseline smear-taking, storage time or date of smear-
taking, and country as well as alive status at the case’s diagnosis were matching 
variables common to all the nested case-control studies, I–IV. In the 
seroepidemiological part of Studies I/II and III, the analytic batch was matched such 
that serum aliquots of a case and its controls were located on the same plate. 
Matching is more detailed in the Janus Serum Bank material than in the other 
biobanks. County is matched in Norway because very different fractions of the 
county populations were sampled by the Janus Serum Bank. Red Cross blood donor 
status was matched in the Janus Serum Bank since the blood donors likely represent 
a healthier fraction of the population than other donors to the biobank (Langseth et 
al. 2010). Using blood donors as controls for population-based cases may result in an 
overestimation of risk, and using population-based controls for blood donor cases 
may result in an underestimation of risk. However, the SIR for cancer of all sites was 
higher among the Janus health examinations than among the blood donor 
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participants. The blood donors are Oslo residents, and a high proportion of health 
examinations donors are from the countryside. Urban inhabitants tend to have a 
higher cancer risk than rural inhabitants. 
In Studies I/II, there was a wide variety of HPV seroprevalences among controls 
by region, which resulted in instability of the estimates. Therefore, the number of 
controls matched to a case was increased from three in Studies I/II to five in Study 
III.  
The rate of HPV16 seroconversion is highest seven to eight months after 
detection of HPV16 DNA (Carter et al. 2000). The same applies to rate of HPV18 
seroconversion after detection of HPV18 DNA. On average 7 to 18 months’ time is 
needed to clear the HPV 18, 31, 33 and 52 infections (Bulkmans et al. 2007, Vänskä 
et al. 2013). Two to three weeks’ time since the onset of symptoms is needed for C. 
trachomatis seroconversion (HM Surcel, personal communication, 9 December 
2013). The mean duration of C. trachomatis infection is 1.4 years (Price et al. 2013). 
On the other hand, rapidly (within 3–6 years) increasing or decreasing over time 
trends affecting the Finnish HPV/C. trachomatis infection incidences/prevalences, 
respectively, during the study period have been documented (Laukkanen et al. 2003, 
Lyytikäinen et al. 2008). These ecological population biology phenomena due to 
changes in risk-taking sexual behaviour (Haavio-Mannila et al. 2001) set constraints 
for observational studies trying to understand interactions of the (most) important 
cervical cancer risk factors. 
Possible confounding by age needs to be considered, especially in the context of 
Study V. Age at first sexual intercourse is a reasonable proxy for age at first 
exposure to HPV among young women (Plummer et al. 2012). Age at first sexual 
intercourse and age at first pregnancy are highly interrelated at least in the less 
developed countries (Louie et al. 2009). They are probably associated with early age 
at first exposure to hrHPV (Winer et al. 2003, Collins et al. 2005). HPV16 attack 
rates were highest among Finnish women with teenage pregnancies (Kibur et al. 
2000) and were high in southwestern Finland among adolescents already in the 
1980s (Lehtinen et al. 2006). In Study V, age at midpoint of consecutive first and 
second pregnancies was in the middle of the age interval of primary interest 
concerning C. trachomatis and type-specific HPV seropositivity and -conversion. 
Age at the midpoint of the first and second pregnancies, at least among the youngest 
women of Study V, was closely associated with early age at first exposure to HPV. 
A co-factor role of long-term (≥10 years) oral contraceptive use has been 
suggested for CIN 3  by Luhn et al. (2013). In their study, a shorter term than 10 
years’ use of oral contraceptives was associated with non-significantly increased risk 
of CIN 3 as compared with women with a milder histological diagnosis than CIN 2. 
Almost half of the Finnish women aged under 25 used oral contraceptives in 2000 
and had used these pills on average for 4 years (Kosunen et al. 2004). Age at first 
pregnancy is a surrogate for age at stopping oral contraceptive use (possibly also 
stopping smoking) before the first pregnancy, and thus is probably associated with 
CIN 3. Furthermore, during the last two decades the curve of age-specific CIN 3 
incidence rates has been steeply increasing in Finnish women under 30 years of age 
(Salo et al. 2013). As the interval between the first and second pregnancies was on 
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average 2.4 years, age at the midpoint of these pregnancies was closely associated 
with age at stopping oral contraceptive use. Thus, confounding by age warranted 
control by stratification.  
Longitudinal designs, in contrast to cross-sectional designs, are necessary for 
studying temporal associations in carcinogenesis, for separating causes and effects. 
To enable representative sampling from biobanks, it is important that population and 
cancer registers are complete and population-based, and that the biobanks are fully 
enumerated. For reliable linkage between serum banks and registers, a unique 
personal identification code number is essential. In studies of cervical 
carcinogenesis, CIN 3/AIS is a feasible outcome, as more than half of the lesions 
may progress to ICC without treatment (McCredie et al. 2008). The final outcome, 
invasive cervical carcinoma, is the most important one since a large proportion of 
precancerous lesions may regress.  
Studies on carcinogenicity usually require a long duration, from exposure until 
cancer diagnosis. Follow-up time was maximized by analysing the first pre-
diagnostic serum sample or baseline smear. The HPV16 IgG antibody levels in 
serum wane very slowly, therefore revealing infections not only at the time of serum 
sampling but also several years before the serum sampling (af Geijersstam et al. 
1998). HPV (capsid) IgG antibodies have been used as markers of cumulative HPV 
exposure (Dillner 2000b, IARC 2007). 
As a subcohort with IgG antibodies for HPV types of interest and C. trachomatis 
at two time points per woman was available, a case-cohort design was ideal for 
meeting Study V objectives. In 6 out of 12 subcohort strata, there were more than 
eight (with a maximum of 174) subcohort members per case in the respective cohort 
stratum. A subcohort like this would not have been sampled for Study V if it had not 
been available from previous studies. Possibly a nested case-control design would 
have been chosen. In nested case-control design, the gain in efficiency is quite 
marginal, with more than four or five controls per case. Although the laboratory 
analyses are highly standardized, there may have been systematic differences 
between the laboratory results of cases and subcohort members due to longer storage 
time of cases’ samples. Study V was the second study applying a case-cohort design 
with cervical neoplasia as the outcome in the Finnish Maternity Cohort, the first 
being that of Laukkanen et al. (2010) on the relative risks associated with hrHPVs 
and the population-attributable fraction of hrHPVs in SCC and CIN 3. 
Factors may strengthen each other’s effect on the risk of disease. When the 
combined or joint effect of two factors is greater than the expected joint effect under 
a statistical model, e.g. additive or multiplicative, it is said that the factors act 
synergistically or that there is synergism. The factors act independently if the joint 
effect is according to formula (1) under additive model or multiplicative if it is under 
multiplicative model. Finally, two factors may weaken each other’s effect. When the 
joint effect of the factors is smaller than the expected joint effect, it is said that the 
factors act antagonistically or that there is antagonism. 
One should avoid saying that there is no interaction instead of no additive 
interaction or no multiplicative interaction, as under another statistical model there 
probably is an interaction and a true biological interaction may exist. Statistical 
 69 
interaction refers to effects at the population level, whereas biological interaction 
refers to effects at the individual level. Biological information to support one scale 
over another is usually not available. Study I focused on multiplicative interaction, 
but the statistical models would have been suitable for estimating also additive 
effects. In Studies II and III, no a priori specification was made for the type of 
statistical interaction. 
An antagonistic interaction was repeatedly found between HPV16 and 
HPV6(/11) in cervical carcinogenesis in both additive and multiplicative models. 
The antagonism was so strong in Studies I/II that there was no excess risk of SCC or 
ICC. The antagonistic interaction was confirmed in the larger, independent material 
of Study III, where the joint effect was antagonistic also regarding the risk of HPV16 
DNA-positive SCC. All joint effects were adjusted for at least cotinine and C. 
trachomatis and HPV18 antibodies. Correction for misclassification bias by applying 
back-calculus and a gold standard suggested that non-differential misclassification 
did not cause the antagonistic interaction. The antagonistic interaction between a 
hrHPV and HPV6/11 was specific to HPV16. In Study I, the joint effect of HPV18, 
which primarily affects columnar cells in the upper cervix, and HPV6/11 suggested 
antagonism, but the larger material of Study III did not support/confirm this 
observation. The joint effects of HPV16 and hrHPV types 18 and 33 were also 
antagonistic regarding the risk for SCC in Study I, but Study III again did not 
support/confirm this observation. 
Silins et al. (1999) reported soon after Study I that in their cross-sectional 
seroepidemiological study the joint effect of HPV6 and HPV16 was antagonistic 
regarding the risk of ICC under both additive and multiplicative models. Chaturvedi 
et al. (2011) reported in their cross-sectional study that the risk of high-grade 
squamous intraepithelial lesion (HSIL) or worse was non-significantly decreased 
among women infected with HPV16 and at least one other HPV type, relative to 
HPV16 alone. In their large, cross-sectional HPV genotyping study, Wentzensen et 
al. (2014) did not find any evidence of synergy between carcinogenic HPV types for 
the risk of HSIL. The risk of HSIL was higher among those with multiple genotypes 
than among those with a single genotype, but the risk was lower than expected on 
the basis of additive effects.  
In a longitudinal study by Trottier et al. (2006), the risk of HSIL associated with 
infections of four to six concurrent HPV types was synergistically increased on the 
additive scale of ORs. Two-year cumulative risks of CIN 3+ for different 
combinations of HPV16, and non-carcinogenic and carcinogenic HPV types at study 
entry were close to but not greater than that for DNA positive for HPV16 only 
(Wheeler et al. 2006). Nauclér et al. (2007) found an antagonistic joint effect 
between HPV6 seropositivity and HPV16 seropositivity on risk of ICC in a 
multiplicative model. Thomsen et al. (2014) reported that 8-year absolute risk of 
CIN 3+ was slightly lower among women who had both an hr- and an lrHPV 
infection at baseline than women who had only hrHPV. 
The antagonistic interaction between different HPV types was probably due to a 
cell-mediated immune reaction (surveillance), the surrogate of which were the serum 
antibodies. A potential explanation for the antagonism between HPV6 and HPV16 in 
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cervical carcinogenesis is that prior infection with HPV6 prevents HPV16 infection 
from becoming persistent and causing cancer (Dillner 2000b).  
Lehtinen and Dillner (2013) reviewed protective efficacies of bivalent HPV16/18 
and quadrivalent HPV6/11/16/18 vaccines against a 6-month persistent cervical HPV 
infection among baseline HPV-seronegative women. The bivalent vaccine showed 
cross-protective efficacy of 35% against non-targeted lrHPV types 6/11 (Szarewski 
et al. 2012). The most notable cross-protective efficacies against non-vaccine hrHPV 
types observed for the bivalent vaccine were 65–77% against HPV31, 32–43% 
against HPV33, 73–79% against HPV45 and 19–20% against HPV52. The 
corresponding cross-protective efficacies of the quadrivalent vaccine were not higher 
against these types, 46%, 29%, 8%, and 18%. Against some non-vaccine types, also 
negative protective efficacies were observed, of up to -56%, but the negative 
estimates were non-significant. Cross-protective efficacy was primarily due to serum 
cross-neutralizing antibodies. The immune response after vaccination is qualitatively 
(more antigenic sites exposed/available) different than in natural infection, but it 
may interfere with the population biology of HPV types in the sexually active 
vaccinated population. 
Unit risk of HPV18 DNA-positive ICC among HPV16-seropositive women, and 
conversely, unit risk of HPV16 DNA-positive ICC among HPV18-seropositive 
women suggest that the two hrHPV types do not affect each other’s risk of cervical 
cancer. Observations of close to unit risks, ORs, 0.9 and 1.1, in corresponding order, 
were made already in the first study material (Sigstad et al. 2002). 
In Study II, the joint effect of HPV16 and C. trachomatis was antagonistic 
regarding the risk for SCC, assuming both multiplicative and additive joint effects, 
but in Study III, the joint effect was close to additive. The RR of C. trachomatis was 
significantly increased among hrHPV seronegatives and HPV18 seropositives, and 
non-significantly among HPV16 seropositives. In Study IV, a highly increased risk 
of invasive cervical cancer was observed among women C. trachomatis DNA-
positive in the prediagnostic smear. The rate ratio estimate was at the same level in 
the same women HPV DNA-positive in the prediagnostic smear (Wallin et al. 1999), 
suggesting that C. trachomatis facilitates (if not replaces) effect(s) of early hrHPV 
infection. It should, however, be noted that the median unbiased estimate for C. 
trachomatis DNA is less reliable than a maximum likelihood estimate. The risk of 
invasive cervical cancer was most increased among women who were positive for 
HPV or C. trachomatis in both the prediagnostic smear and cancer biopsy. 
In Study V, the HPV16 adjusted risk of cervical precancer was highly increased 
among women who were HPV31 seropositive before becoming HPV6 seropositive 
as compared with HPV6 seropositivity before HPV31 seropositivity. This is in line 
with the longitudinal studies cited above. Within the time-windows/time-constraints, 
it also suggests that natural infection with benign HPV types acts as a natural (alive) 
vaccination against (consequences of) infections with an oncogenic HPV type. It 
sheds light on the success of prophylactic HPV vaccines and suggests that the 
mechanisms and consequences of (cross-)protection warrant further research. 
The risk of CIN3 was similar whether HPV6 seropositivity was before or after 
HPV33 seropositivity. This is in line with the suggested competitive advantage of 
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HPV33 over other common low- and high-risk HPV types (Merikukka et al. 2011). 
The rate ratios associated with HPV18/45 seroconversion did not differ between 
HPV6 seroconverters and HPV6 seropositives at first sampling. The same applied to 
rate ratios associated with HPV18/45 seropositivity at first sampling.  
The highest rate ratio estimate was observed for dual seroconversion of 
HPV18/45 and C. trachomatis between two consecutive pregnancies as compared 
with dual seronegativity to the infections at both samplings during the first 
trimesters. This indicates that virtually overlapping infections with HPV18/45 and C. 
trachomatis in the cervix <are especially carcinogenic. It is in line with an 
independent role for C. trachomatis in cervical carcinogenesis (Lehtinen et al. 2011) 
and suggests that C. trachomatis screening might have an effect on cervical 
neoplasia occurrence. 
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7 CONCLUSIONS 
In the first longitudinal nested case-control study (I), excess risk of developing ICC 
among women seropositive for both the most carcinogenic HPV16 and the non-
carcinogenic HPV6/11 was non-existent. This finding was supported by the second 
similar, albeit larger study (III) reporting a significantly smaller risk of developing 
ICC among women seropositive for both HPV16 and HPV6 than expected on the 
basis of multiplicative and additive joint effects. Other study groups have since 
reported similar results. Furthermore, the result of the most recent study (V), that the 
orders of major lrHPV type 6 and hrHPV type 31 have considerably different effects 
on risk of CIN 3/ICC, confirms the biological plausibility of the original finding of 
antagonistic interaction. The risk of CIN 3/AIS was 23 times higher if HPV31 
preceded HPV6 than the reverse scenario. Earlier HPV6 infection and associated 
immune response may well prevent HPV16 and HPV31 from becoming persistent. 
The antagonistic interaction was probably due to cell-mediated immune response 
and associated immune surveillance. The finding that infection with a non-
carcinogenic HPV type may act as a natural vaccination against high-risk HPV types 
supports HPV vaccination in cervical cancer prevention. The antagonistic additive 
interaction or even absence of an excess risk suggests that there is a public health 
interaction to be considered. 
There was no excess risk of HPV18 DNA-positive ICC associated with HPV16 
seropositivity, and also no excess risk of HPV16 DNA-positive ICC associated with 
HPV18 seropositivity. This is in line with type-specific HPV DNA persistence of 
these major oncogenic HPV types in cervical carcinogenesis. 
The risk of SCC associated with C. trachomatis remained increased after 
adjusting for HPV, both in the total material and in HPV18-seropositive women. 
Virtually concomitant seroconversion for both C. trachomatis and HPV18/45, i.e. 
virtually concomitant infections, were associated with highly increased risk of CIN 
3/AIS. Concomitant C. trachomatis and hrHPV infections should be considered in 
the preventive efforts against cervical cancer. 
The public health implication of these studies is a support to the early HPV 
vaccinatioin in cervical cancer prevention. 
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TECHNICAL APPENDIX 1 – THE NORDIC 
REGISTER DATA BASES UTILIZED IN THE 
STUDIES 
Cancer registries and registration in Finland, Iceland, Norway and 
Sweden 
 
(Referred to on page 46.) 
 
The Finnish Cancer Registry is technically run by the Cancer Society of Finland, but 
is supervised by the National Institute for Health and Welfare, which owns the 
original patient data. The Icelandic Cancer Registry has been run by the Icelandic 
Cancer Society since 1954. The Directorate of Health has been responsible for the 
registration from 2007 onwards. The Cancer Registry of Norway is part of the 
South-Eastern Norway Regional Health Authority and an independent institution 
under Oslo University Hospital Trust. In Sweden, the local authorities of the 21 
counties own and are responsible for the cancer data. The regional cancer registry at 
the Oncological Centre in Umeå has collected data since 1978. 
The cancer registries are population-based. The populations include all residents 
in the areas who are entered in the official population statistics and have been given 
a personal identification number (Association of the Nordic Cancer Registries 2000). 
The primary basis of diagnosis is morphology. Morphological confirmation of 
diagnosis was available for 92–100% of invasive cervical cancers at the national 
cancer register in Finland during 1983–1994 (Finnish Cancer Registry 1987–1996). 
All cases of invasive cervical cancer were morphologically verified in Iceland in 
2005–2009 (Sigurðardóttir et al. 2012). In Norway, the proportion was 97.4% during 
1989–1993 (Cancer Registry of Norway 1996) and 99.8% during 2001–2005 (Larsen 
et al. 2009).  
The date of diagnosis is the earliest date on the received notification form 
(Association of the Nordic Cancer Registries 2000). The date of in situ carcinoma of 
cervix uteri diagnosis is the date of invasive cervical cancer diagnosis, if the new 
invasive tumour is diagnosed within 2 months of in situ diagnosis in Iceland, within 
4 months in Norway and within 1 year in Finland and Sweden. 
Up to and including 2006, Finnish Cancer Registry coded topography according 
to a modified version of International Classification of Diseases, 7
th
 revision (ICD-7) 
(WHO 1957), and morphology according to the Manual of Tumor Nomenclature and 
Coding (MOTNAC) (American Cancer Society 1951). Since 2007, topography and 
morphology have been coded according to the International Classification of 
Diseases for Oncology, 3rd edition (ICD-O-3) (Fritz et al. 2000). The ICD-7 and 
MOTNAC codes have been translated into ICD-O-3. 
The Cancer Registry of Norway coded topography according to ICD-7 in 1952–
1982 and morphology according to a modified version of MOTNAC in 1968–1992 
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(American Cancer Society 1968). Since 1993, topography was coded according to 
ICD-O-2 (Percy et al. 1990) with the topography axis standardized with ICD-10, and 
morphology using ICD-O-2 with local modifications (Larsen et al. 2009). 
Topography was converted to ICD-7 codes. 
Icelandic Cancer Registry coded topography according to ICD-9 since 1980 
(WHO 1977), ICD-O-1 since 1983 (WHO 1976) and ICD-O-2 during 1991–2002 
(Sigurðardóttir et al. 2012). Conversions to ICD-7 and ICD-9 are still done 
automatically. Morphology was coded according to the Systematized Nomenclature 
of Pathology until 1983 and since then according to the Systematized Nomenclature 
of Medicine (Wells 1965, Côté 1979). 
In Sweden, morphology was coded according to C24 (WHO/HS/CANC/24.1) 
since 1958 and ICD-O-2 during 1993–2004. Topography was coded according to 
ICD-7 since 1958, ICD-9 since 1987 and ICDO-2/10 during 1993–2004. The codes 
were translated into ICD-7 and ICD-9. 
 
 
High-grade cervical precancer at the Finnish Cancer Registy (V) 
 
The Finnish Cancer Registry registers the following high-grade cervical precancers 
(ICD-O-3 codes for morphology/behaviour in parentheses), carcinoma in situ, not 
otherwise specified (M8010/2), squamous cell carcinoma in situ (M8070/2), 
dysplasia gravis (M6666/0), cervical intraepithelial neoplasia grade 3 (M8077/2) and 
adenocarcinoma in situ (M8140/2). Initially, carcinoma in situ was the only 
diagnostic term for high-grade cervical precancer. Registration of dysplasia gravis 
(severe dysplasia) and CIN 3 became official practice in the early 1990s (Hakama et 
al. 2004). All of the terms are still in use. In the following, all lesions except AIS 
will be called CIN 3. Registration of the CIN 3/AIS lesions was estimated to be 80% 
complete in 1998–2007 (Lönnberg et al. 2012). 
 
 
Care Register for Health Care (V) 
 
(Referred to on page 50.) 
 
The Care Register for Health Care collects in Finland data on the activities of 
institutions providing inpatient care and on the clients treated in them as well as on 
home-nursing clients for the purposes of statistics, research and planning. The data 
are controlled by the National Institute for Welfare and Health. The Care Register 
for Health Care replaced the Hospital Discharge Register since 1994. The Hospital 
Discharge Register contained data only on patients discharged from inpatient care in 
hospitals, whereas the Care Register contains also outpatient data, e.g. on day 
surgeries. The register covers more than 95% of discharges, and positive predictive 
value for common diseases varies between 75% and 99% (Sund 2012). 
 
 
 109 
Population Information System (V)  
 
(Referred to on page 49.) 
 
The Population Register Centre, founded in 1969, and the local register offices are 
controllers for the Finnish Population Information System. The Population Register 
Centre maintains and develops the Population Information System, its data and data 
quality. The Population Information System contains information on, for example, 
the time of death or the time of declaring a person dead, the municipality and the 
place of residence therein and the date of emigration. Statistics Finland is responsible 
for statistics on causes of death and maintains death certicificates since 1936. The 
statistics are based on data in death certificates and data on deaths in the Population 
Information System. The cancer register receives data on emigrations from the 
Population Register Centre and data on deaths from Statistics Finland. 
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TECHNICAL APPENDIX 2 – RE-
EXAMINATION OF HISTOLOGY (II–IV) 
The histological slides of 182 cases included in Study I and four cases excluded from 
that study (one leiomyosarcoma and three without reported histology) were retrieved 
for histological reclassification by two pathologists (E Sigstad and V Abeler). The 
reviewers were blinded to the registered diagnoses. The tumours were classified and 
graded according to an international histological classification of tumours blinded to 
registered diagnosis (Poulsen et al. 1975). The first biopsy or best-preserved 
specimen of 127 cases could be located, verified to contain ICC, and amplified by 
PCR (Sigstad et al. 2002). Paraffin rolls (5 cases) could not be tested for 
contamination and were not analysed by PCR. One hundred and seven of them were 
SCCs. Five of them were of other histology in Study I, and two were excluded from 
Study I due to no reported histology. The histology of eight SCCs in Study I changed 
in histological reclassification. There were 178 cases and 527 controls after 
histological reclassification. 
Study II concentrated on SCC. The SCCs of Study I were not excluded from 
Study II if the histological specimen for the review was missing or non-
representative. The SCCs reclassified as precancerous were not excluded if there was 
independent information of invasion. There were 148 SCCs and 438 matched 
controls. 
For Study III, two senior pathologists (W Ryd and F Bergman) re-examined 
sections of paraffin-embedded cancer tissues and if available histopathological slides 
for confirmation of cervical cancer diagnosis. Icelandic legislation forbade export of 
cancer tissues and histopathological slides. 
For Study IV, a senior pathologist (F Bergman) re-examined all histological 
slides for confirmation of cervical cancer diagnosis. 
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(Referred to on pages 46 and 47.) 
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TECHNICAL APPENDIX 3 – THE GREY 
ZONES 
For the cases not in the subcohort, grey zones of HPV type 6/16/18/31/33/45 
antibodies were [0.2823,0.4837], [0.2674,0.4526], [1.1754,1.7906], [0.8758,1.3842], 
[0.8667,1.3533], [0.9278,1.4122] absorbance units (optical density at 405 nm), 
respectively. The grey zones for antibodies to HPV type 6/16/31/33/45 for the 
subcohort members were [0.3798,0.6202], [0.2674,0.4526], [0.3957,0.6243], 
[0.3834,0.5986], [0.3507,0.5433] absorbance units, respectively. The subcohort 
members had different grey zone for HPV18 antibodies at first sample 
([0.3299,0.4911] absorbance units), and at second sample ([0.3149,0.4751] 
absorbance units). 
 
(Referred to on page 51.) 
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ERRATA 
In Publication I, on page 822 in the numerical example of the “Appendix”, 
specificity of HPV16 and HPV6/11 antibody assays, Sx and Sy, should be 0.99 
instead of 0.98.  
 
In Publication III on page 2546, two rows of Table 3 are missing. In the table block 
of C. trachomatis, below row 
“        2,471 controls        1,920 controls        2,584 controls        2,010 controls” 
there should be row 
“        HPV type 16 seronegativesa                          HPV type 18 seronegativesb“  
and in the table block of HSV-2 below row 
“        2,471 controls        1,920 controls        2,584 controls        2,010 controls”  
there should be row 
“        HPV type 16 seronegativesc                          HPV type 18 seronegativesd“. 
 
In Publication III on page 2548, there should not be in the footnote of Table 8 rows  
“P for multiplicative interaction = 0.0036 
RERI = -0.645 95% CI (-2.5, -1.2). 
P = 0.49”. 
 
(Referred to on page 58.) 
